The Proteomic Landscape of Breast Cancer Metabolism by Bernhardt, Stephan
  
 
Dissertation 
 
 
submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
 
 
Doctor of Natural Sciences 
 
 
presented by 
 
Diplom-Biochemist Stephan Bernhardt 
born in: Dessau, Germany 
 
 
 
Oral-examination: 06.11.2017 
 
 

  
 
The Proteomic Landscape 
 of 
Breast Cancer Metabolism 
 
 
 
 
 
 
 
 
 
 
 
Referees: Prof. Dr. Stefan Wiemann 
     PD Dr. Ralf Bischoff 
 
 

  
 
 
 
„Borders? I have never seen one. But I have heard they exist in 
the minds of some people” 
 
Thor Heyerdahl 
 
 
 
 
 
 
 
 
 
 
 
 
For my Parents & Jennifer 
 
 

Declaration of Authorship 
 
I hereby declare that the work presented in my dissertation was carried out from June 
2013 to June 2017 under joint supervision of Dr. Ulrike Korf† and Prof. Dr. Stefan 
Wiemann in the Division of Molecular Genome Analysis at the German Cancer 
Research Center (DKFZ, Heidelberg, DE). 
 
If not stated otherwise and referenced within the text, the data presented in my 
dissertation is original, has been performed by myself and has not yet been presented 
as part of a university examination. Sources that were used and collaborative work 
have been indicated appropriately. I declare no potential conflict of interest. 
 
Parts of this thesis have been published in: 
 
Bernhardt, S., Bayerlová, M., Vetter, M., Wachter, A., Mitra, D., Hanf, V., Lantzsch, 
T., Uleer, C., Peschel, S. John, J., Buchmann, J., Weigert, E., Bürrig, K., Thomssen, 
C., Korf, U., Beissbarth, T., Wiemann, S. and Kantelhardt, E. Proteomic profiling of 
breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. Breast 
Cancer Research, (2017 in revision) 
 
Wachter, A., Bernhardt, S., Beissbarth, T. and Korf, U. Analysis of Reverse Phase 
Protein Array Data: From Experimental Design towards Targeted Biomarker 
Discovery. Microarrays 4, (2015) 
 
Sonntag, J., Schluter, K., Bernhardt, S. and Korf, U. Subtyping of Breast cancer using 
reverse phase protein arrays. Expert Review of Proteomics 11, (2014) 
 
 
 
Heidelberg, 
 
S. Bernhardt 
 

Acknowledgements 
 
Firstly, I would like to express my deepest gratitude to my former supervisor Dr. Ulrike 
Korf†. She always encouraged me to pursue my ideas and to embrace scientific 
resilience. I was deeply saddened to lose a close mentor and extraordinary scientist. 
I am very grateful to my supervisor and examiner Prof. Dr. Stefan Wiemann for giving 
me the opportunity to work in his division, and for the scientific and financial support. 
He also has been part of my thesis advisory committee (TAC), and took over my 
supervision in difficult times whilst still providing me with the scientific freedom and 
encouraging me to work independently. 
Furthermore, I would like to thank my other TAC members and examiners, Prof. Dr. 
Peter Angel, Prof. Dr. Stephan Frings, PD Dr. Ralf Bischoff, Dr. Aurelio Teleman and 
Prof. Herbert Steinbeisser† for giving me their time and guidance. 
My PhD project wouldn’t have been possible without collaborations and therefore I 
like to thank Prof. Dr. Tim Beißbarth and Prof. Dr. Jens Timmer as well as the talented 
bioinformaticians Dr. Astrid Wachter, Dr. Michaela Bayerlová and Christian Tönsing 
who have helped me along the way and who performed exceptional analysis for my 
study. 
Likewise, I would like to thank Prof. Dr. Christoph Thomssen, who kindly assisted my 
collaboration with Dr. Eva Johanna Kantelhardt and Dr. Martina Vetter, who 
generously supported my PhD project with clinical specimens and clinical 
information. 
Moreover, I thank my fellow PhD students of the Division Molecular Genome 
Analysis of the German Cancer Research Center for the enjoyable working 
environment throughout the years and wonderful time also outside the lab. 
Finally, I want to thank my girlfriend Jennifer and my family for their constant support 
and encouragement during my PhD and beyond. 
 

Summary 
 
Breast cancer tumors are recognized to be highly heterogeneous, and differences in 
their metabolic phenotypes are less well understood. While a number of mostly RNA-
based profiling approaches have been developed aiming to improve diagnostic and 
therapy decision, few have entered clinical practice. Alongside metabolic alterations, 
tumor hypoxia has consistently been associated with a more aggressive malignant 
phenotype. Both tumor hypoxia and dysregulated metabolism are classical features of 
cancer and currently no studies either systematically examine the prognostic value of 
metabolism associated enzymes in a large cohort of breast cancer patients or their 
alterations in oxygen deprived conditions. 
For my PhD project, I undertook systematic profiling of metabolic enzymes in a cohort 
of 801 breast cancer patients to evaluate the relationship between profiles of 
metabolism-associated protein expression and clinicopathological characteristics. I 
identified three metabolic clusters of breast cancer that are significantly correlated with 
overall and recurrence-free survival, but do not reflect the common receptor-defined 
subtypes. Furthermore, high protein expression of the Serine Hydroxy-
methyltransferase 2 (SHMT2) and the Amino Acid Transporter (ASCT2), were 
identified as independent prognostic factors for overall and recurrence-free survival in 
breast cancer patients. 
Another aspect of research revealed the heterogeneous regulation of metabolic 
enzymes during oxygen deprived conditions and elucidated glutamate-ammonia ligase 
(GLUL) as a novel effector of the hypoxic response in breast cancer cell lines. 
The findings of my thesis are the first to demonstrate metabolic heterogeneity at the 
protein level in a large breast cancer cohort and highlight the clinical significance of 
SHMT2 and ASCT2 protein expression as new independent prognostic markers in 
breast cancer patients. Additionally, GLUL protein expression was identified as a 
novel effector of the hypoxic rewiring process in breast cancer cell lines. These 
findings may pave the way for the utilization of SHMT2 and ASCT2 as potential 
targets for innovative personalized therapy and advance the understanding of 
metabolic adaptation during hypoxic conditions. 
 

Zusammenfassung 
 
Das Mammakarzinom ist eine heterogene Tumorentität, wobei Unterschiede in 
Tumormorphologie und deren metabolischen Phänotypen bisher wenig erforscht sind. 
RNA-basierte Untersuchungstechniken wurden entwickelt, um die Diagnose- und 
Therapieentscheidung von Brustkrebs Patientinnen zu verbessern, jedoch nur wenige 
haben Eingang in die klinische Routine gefunden. Neben metabolischen 
Veränderungen ist auch die Tumorhypoxie mit einem aggressiveren Phänotyp 
assoziiert. Sowohl Tumorhypoxie, als auch ein dysregulierter Stoffwechsel stellen 
klassische Merkmale von Krebszellen und Tumoren dar. Derzeit gibt es keine Studien, 
die die prognostische Aussagekraft Stoffwechsel assoziierter Enzyme in einer großen 
Kohorte von Brustkrebspatientinnen untersuchen, bzw. die metabolischen 
Veränderungen in hypoxischen Bedingungen auf breiter Proteinebene abbilden. 
Im Rahmen dieser Promotionsarbeit, erfolgte die systematische Untersuchung 
Metabolismus-assoziierter Enzyme in einer Kohorte von 801 Brustkrebspatientinnen, 
um die Beziehung zwischen Proteinexpressionen und klinischen bzw. pathologischen 
Eigenschaften zu bewerten. Drei Cluster konnten identifiziert werden, die signifikant 
mit dem Gesamt- und Rezidiv-freien Überleben korrelieren, jedoch nicht die Rezeptor-
definierten Subtypen reflektieren. Darüber hinaus wird das Ausmaß der 
Proteinexpression der Serin-Hydroxy-methyltransferase 2 (SHMT2) und des 
Aminosäure-Transporters (ASCT2) als unabhängige prognostische Faktoren für das 
Gesamt- und Rezidiv-freie Überleben bei Brustkrebspatienten beschrieben. 
Unter hypoxischen Bedingungen konnte zudem eine heterogene Regulation von 
metabolischen Enzymen gezeigt werden. Hierbei wird die Glutamat-Ammoniak-
Ligase (GLUL) als neuer Effektor der hypoxischen Adaption in Brustkrebszelllinien 
vorgestellt. 
Die Ergebnisse meiner Arbeit zeigen erstmals die metabolische Heterogenität auf 
Proteinebene in einer großen Kohorte und demonstrieren die klinische Bedeutung der 
SHMT2 und ASCT2-Protein-Expression als neue unabhängige prognostische Marker 
bei Brustkrebspatientinnen. Basierend auf diesen Ergebnissen können SHMT2 und 
ASCT2 als potenzielle Kandidaten für innovative personalisierte Therapien weiter 
untersucht werden. Zusätzlich konnte die Expression von GLUL als neuer Effektor 
  
des hypoxischen Adaptionsprozesses in Brustkrebszelllinien identifiziert und so das 
Verständnis der metabolischen Anpassung während hypoxischer Bedingungen 
erweitert werden. 
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1.1  Hallmarks of cancer 
 
The Hallmarks of cancer represent acquired features of cancer cells during 
carcinogenesis. First introduced in 2000 by Hanahan and Weinberg, they comprised 
limitless replicative potential, evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, sustained angiogenesis, tissue invasion and 
metastasis [1]. Due to extensive research in the field of oncology, more than a decade 
later, Hanahan and Weinberg revised the classical hallmarks of cancer and added four 
new additional features. These novel hallmarks represent tumor-promoting 
inflammation, genome instability, immune system evasion, and dysregulated energy 
metabolism [2]. Taken together, these functional features of abnormal cell growth, 
represented in diverse cancer genotypes and phenotypes, are adaptive strategies to 
overcome specific microenvironmental growth constraints such as hypoxia and enable 
cancer development [3]. Especially cancer metabolism, as new hallmark of cancer, is 
of particular interest to my PhD project and its proteomic investigation represents the 
main part of this thesis (Figure 1). 
 
Figure 1 - Hallmarks of cancer: A focus on cancer metabolism. 
Hallmarks of Cancer, as illustrated in this figure, are either modulated by metabolic changes 
or affect metabolism. The schematic overview was adapted from Lewis and Haleem, 2013 [4]. 
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1.2  Breast cancer 
 
1.2.1 Epidemiology, etiology and pathology 
Worldwide, breast cancer (BC) is the most prevalent cancer entity among women and 
commonly known as a heterogeneous disease in terms of tumor morphology and 
molecular structure [4], [5], [6]. The majority of the increasing incidence of breast 
cancer cases and deaths, occur in less developed regions with low health expenses per 
capita. Despite the increase in breast cancer cases, mortality rates have decreased, 
mainly due to screening programs, earlier detection of the disease, a deeper 
understanding of the tumor biology, and the development of novel therapeutic 
strategies for the treatment of patients [7]. 
The heterogeneity of breast tissue is reflected in its morphology. Surrounded by 
stromal tissue, the luminal epithelial cells are enveloped by myoepithelial cells that 
enclose lobules and ducts. Breast cancer refers to several types of neoplasm arising 
from breast tissue. Differences in the local microenvironment and cellular 
differentiation states can give rise to phenotypically diverse tumors [8], [9]. Several 
risk factors like germline mutations, radiation exposure, age, gender, family history, 
alcohol and obesity have been associated with breast cancer development [10]. The 
disease is accompanied by a number of symptoms such as a lump in the breast or nipple 
discharge, and while it is often diagnosed after spread has occurred, the diagnosis at 
screening (ultrasound or mammography) is increasing [11]. 
Histologically, breast tumors are classified based on their structural organization and 
their morphology. Patient tumors are graded based on the degree of cellular 
pleomorphism, tubular/gland formation, and number of mitoses. Associated with poor 
outcome are the presence of necrosis, lack of an inflammatory cell reaction, and 
lymphatic and blood vessel invasion. Furthermore, the presence or absence of lymph 
node involvement has a strong effect on relapse, rather than the amount of lymph nodes 
involved [12]. 
Routine pathological assessment, usually performed by immunohistochemistry (IHC), 
includes the determination of estrogen receptor (ER) and progesterone receptor (PR) 
status, which help to predict which patients will benefit from hormonal therapy [13], 
Chapter 1 
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[14]. In addition, the human epidermal growth factor receptor 2 (HER2) is also 
measured as its oncogenic amplification and/or overexpression has an adverse 
prognostic effect [15]. Cancers overexpressing ER or HER2 are suitable for targeted 
therapy, like monoclonal antibodies binding to the receptor and disrupting the 
signaling cascade [16]. 
 
1.2.2 Staging and markers of prognosis 
Current methods of staging include clinical and pathological information as well as 
biological assessment. The most commonly used classification is the UICC 
(International Union Against Cancer) and TNM (Tumor, Node, Metastasis) 
classification systems, where tumors are classified by size, number of regional lymph 
nodes and presence or absence of distant metastases [17]. However, the disease course 
is heterogeneous and while some patients survive for years after developing 
metastases, others’ disease rapidly progresses despite treatment. 
The limitations of pathological information for predicting response to treatment, have 
led to increasing interest in biomarkers such as gene expression signatures and 
complemented data obtained from histological and immunohistochemical profiling 
[18]. Gene expression profiling has had a considerable impact in understanding breast 
cancer biology. During the last decade, intrinsic molecular subtypes of breast cancer 
(Luminal A, Luminal B, HER2-enriched, Basal-like) and a normal breast-like 
subgroup have been identified and intensively studied [19]. Recent technological 
advances and tremendous efforts of consortia like The Cancer Genome Atlas (TCGA) 
and the Molecular Taxonomy of Breast cancer International Consortium 
(METABRIC) have further increased our understanding of the molecular pathways 
and their heterogenous derangements in human solid tumors [20]. A combined 
evaluation of recurrent gene mutations, gene copy number alterations, and 
transcriptomic profiles has led to a refinement of the molecular classification of breast 
cancer (Figure 2). Subtypes can now be defined by multiparameter molecular tests 
such as the MammaPrint/BluePrint or Prediction Analysis of Microarray (PAM) 50 
[21], [22]. However, in clinical practice, the key question is not the separation of 
molecularly defined intrinsic subtypes, but rather the discrimination between patients 
who will or will not benefit from particular therapies. Several of the multiparametric 
Introduction 
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molecular markers have been utilized for this purpose [23], [24]. However, none has 
received approval in Germany yet for routine testing and therapy decision [25]. 
 
 
Figure 2 - Breast cancer pathogenesis and molecular subtypes. 
This figure was adapted from Sims et al., 2007 [26]. 
 
Although many genes and proteins have been investigated as prognostic and predictive 
factors, only a few are currently decisive for treatment. For now, available predictive 
models to inform the systemic treatment of individual patients are still limited to a few 
established biomarkers (mainly hormone receptor and HER2 status, and markers of 
cell proliferation like Ki67). 
A predictive biomarker gives information about the effect of a therapeutic intervention, 
whilst, a prognostic biomarker provides information about the patient’s overall cancer 
outcome regardless of therapy. So far, just a few predictive biomarkers and signatures 
like the ‘Oncotype Dx’ have been evaluated in large scale clinical trials [27], [28]. 
 
1.2.3 Treatment and therapy 
The current standard of care for patients with primary breast cancer is local 
management, including surgery and radiotherapy, with or without systemic therapy, 
Chapter 1 
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depending on the tumor type and stage. Successful cancer treatment requires the early 
removal of the tumor cells to prevent recurrence and metastasis, which is the main 
cause of mortality. If suitable, patients receive neoadjuvant therapy to shrink the tumor 
before treatment and to allow a breast-conserving surgery. Patients who have no 
detectable cancer after surgery can be given adjuvant systemic therapy to treat micro 
metastases. 
Stage I and II tumors are usually treated with breast conserving surgery as well as 
radiotherapy, while Stage III or IV, representing large tumors, may require 
mastectomy. A systemic therapy may involve hormone treatment, like tamoxifen or 
aromatase inhibitors and chemotherapy. The treatment protocol depends on 
stratification factors like patient’s age, menopausal status, ER status and HER2 status, 
Tumor (T) stage, and with increasing prevalence also genomic screening [29]. Please 
refer to Table 1, adapted from Senkus et al. (2015), for systemic treatment 
recommendations [30]. 
 
Table 1 - Systemic treatment recommendations for breast cancer subtypes 
Subtype Recommended therapy Comments 
Luminal A-like ET alone in the majority of cases ChT if:   
high tumor burden (four or more 
positive LN, T3 or higher)   
grade 3 
Luminal B-like  
(HER2-negative) 
ET + ChT for the majority of 
cases 
 
Luminal B-like  
(HER2-positive) 
ChT + anti-HER2 + ET for all 
patients 
If contraindications for the use of 
ChT, one may consider ET + anti-
HER2 therapy 
HER2-positive 
(non-luminal) 
ChT + anti-HER2 
 
Triple-negative 
(ductal) 
ChT 
 
ET, endocrine therapy; ChT, chemotherapy; LN, lymph node. 
 
Recently, preclinical studies underline the importance of the immune landscape and 
point towards the additional benefit of combining treatments aimed at the immune 
system. Immune-targeted drugs , like PD-1 inhibitors may be suitable in this setting 
[31]. Another issue based on the broad use of hormonal therapy, is overcoming 
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endocrine therapy resistance. Combining endocrine agents and blockers of growth 
factors might be a useful strategy in this context [32]. 
The heterogeneity of breast cancer is an ongoing challenge for clinicians, as patients 
with breast cancer and identical clinicopathological characteristics often present 
markedly distinct outcomes. There is a clear need to identify additional markers to help 
patient stratification and selecting those patients that may benefit from a certain type 
of therapy. Therefore, biomarker discovery approaches in areas of the new hallmarks 
of cancer, like the proteomic exploration of cancer metabolism during my PhD project, 
might pave the path for a better patient stratification and prognosis evaluation. 
  
Chapter 1 
10 
  
Introduction 
11 
 
1.3 Cancer metabolism 
 
1.3.1 Rewiring of cellular metabolism in cancer 
Altered metabolism has been known to characterize tumors ever since Otto Warburg, 
in the 1920s, reported his first observations of metabolic changes that accompany 
malignancy [33]. Moreover, deregulated cancer metabolism has regained attention and 
is regarded as a new hallmark of cancer [34]. 
Cancer cells differ from healthy cells due to extensive molecular changes, many of 
which are mechanistically linked to metabolic reprogramming. Proliferative cells as 
well as tumor cells alter their metabolism in order to support biosynthetic reactions 
required for accumulation of biomass and the production of macromolecules [35]. 
Classical features of cancer may be conditioned by metabolic reprogramming, or 
metabolic reprogramming may be the consequence of nonmetabolic oncogenic events, 
such as constitutive activation of growth factor pathways, HIF-1 activation, and 
inactivation of p53 [36]. Moreover, in this context, somatic mutations in oncogenes as 
well as environmental conditions like inflammation or hypoxia have been shown to 
cooperate in generating the malignant phenotype [35]. 
Cancer cells require large amounts of energy and therefore increase their uptake of 
carbon units with glucose and amino acids as their main sources [35]. Furthermore, 
oncogenes and tumor suppressors have been shown to directly control many of these 
adaptations, and consequently, most tumor cells display altered metabolism compared 
to normal cells [37]. This metabolic rewiring in cancer cells provides a continuous 
supply of building blocks and supports the production of intermediates for lipid, 
protein and nucleotide synthesis. Metabolic transformations have been intensively 
studied over the past decade and as a result, first therapeutic strategies are emerging 
which target altered metabolism of cancer cells [38]. 
 
1.3.2 The Warburg Effect 
Historically, the field of cancer metabolism has been rooted in discoveries of the 
German biochemist Otto Warburg in the 1920s [39]. He and his colleagues observed 
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that proliferative cells use glycolysis for adenosine triphosphate (ATP) production 
even in the presence of oxygen and that tumor cells, unlike most normal cells, utilize 
glycolysis rather than oxidative phosphorylation (OXPHOS) for ATP production 
(Figure 3). The consequences of this metabolic adjustment are increased glycolytic 
activity and enhanced lactate secretion, also termed aerobic glycolysis and later known 
as the “Warburg effect” [34]. 
 
 
Figure 3 - Energy pathway comparision. 
Depicted are differences between oxidative phosphorylation, anaerobic glycolysis, and 
aerobic glycolysis (Warburg effect). The Figure was adapted from Vander Heiden et al., 
2009 [40]. 
 
For energy production in normal cells, pyruvate is mainly oxidised in the mitochondria 
via the tricarboxylic acid cycle (TCA) and under low oxygen conditions, pyruvate is 
converted into lactate (anaerobic metabolism). Cancer cells primarily use the 
anaerobic metabolism route. Several explanations have been proposed to describe this 
phenomenon. Although aerobic glycolysis is less efficient than the OXPHOS in terms 
of ATP molecules produced per cycle, it has been discussed that tumor cells with 
glycolytic driven metabolism progress rapidly due to their enhanced glycolytic flux 
and competitive advantage over their normal counterparts [41]. Since, the production 
of ATP molecules reaches/exceeds that of oxidative phosphorylation due to the 
Introduction 
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increased glycolytic flux, the ATP levels meet the demand of highly proliferating cells 
[40]. Furthermore, lactate, the main end product of aerobic glycolysis provides acidic 
conditions causing an environment in favour of tumour invasion and suppressing 
anticancer immune effectors. Cancer cells may also favour aerobic glycolysis over 
mitochondrial respiration to minimise the generation of reactive oxygen species 
(ROS). The metabolic re-programming in cancer is essential for redox balance and the 
synthesis of fatty acids, amino acids and nucleotides to generate macromolecules for 
cell growth [42], [43]. The extensive increase in glucose uptake by cancer cells also 
leads to clinical progress in the field of radiology, where glucose uptake is exploited 
clinically to visualize tumours by 2-(18F)-fluoro-2-deoxyD-glucose positron emission 
tomography (FDG-PET) [44]. 
Nevertheless, tumor cells require more than glucose molecules and glycolytic 
intermediates for their needs to achieve the production of necessary metabolites [45]. 
In fact, in proliferating cells, glucose alone cannot be used for carbon catabolism and 
for ATP production. High levels of ATP would impair Coenzyme A production, and 
consequently another energy source is needed for replenishing the TCA cycle with 
intermediates for the biosynthesis of macromolecules. In particular, for restoring 
Oxaloacetic acid levels, which are impaired by the export of citrate from the 
mitochondria in order to synthesize lipids, tumor cells exploit a different source: 
glutamine [46]. 
 
1.3.3 Glutamine metabolism 
After glucose, glutamine represents the most prominent carbon resource for synthesis 
of the three major classes of macromolecules (Figure 4) [47], [46]. It is also the most 
abundant amino acid in human plasma and a fundamental source for nucleotide, amino 
acid and glutathione (GSH) synthesis [48], [49]. 
The primary functions of glutamine are the storage and transport of nitrogen in the 
muscle and between organs. Besides its various functions, glutamine is also required 
for the regulation of the cellular redox potential. Glutamine metabolism provides 
precursors for the synthesis of GSH, the major thiol containing endogenous 
antioxidant, which serves as a redox buffer against various sources of oxidative stress. 
During glutaminolysis, defined as a metabolic process where glutamine is converted 
to α- ketoglutarate via glutamate, glutamine acts as a nitrogen donor to provide 
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building blocks for further synthesis of nonessential amino acids [50]. Glutamine itself 
is traditionally considered a nonessential amino acid, but during periods of rapid 
growth, the demand for glutamine exceeds its supply and it becomes essential. 
 
 
Figure 4 - Glutamine metabolism. 
The Figure was modified from Wise et al., 2010 [51]. OAA, Oxaloacetic acid; Ac-CoA, Acetyl-
Coenzyme A.  
 
Glutamine can be utilized by the cell to generate the amino acids arginine and proline. 
In addition to their function as precursors for protein synthesis, proline can act as an 
antioxidant and arginine is involved in nitric oxide signalling [52], [53]. Moreover, 
glutamine shuttling across the plasma membrane is necessary for the import of 
essential amino acids such as phenylalanine [54]. Glutamine itself is transported by 
several families of amino acid transporters, of which the Na+-dependent ASCT2 
transporter, also named SLC1A5 (Solute Carrier Family 1 Member 5), belongs to the 
most ubiquitously expressed glutamine transporters in human cancer cells [55]. 
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High glucose and glutamine uptake is a common feature of tumor cells and is 
associated with increased secretion of metabolic by-products such as lactate, alanine 
and ammonia. [56]. The so-called ‘glutamine addiction’, which is characterized by 
poor cancer cell survival in the absence of glutamine, has been observed in several 
cancer entities [57]. Glutamine addicted cells alter their transcriptional programme to 
upregulate the expression of glutamine transporters and enzymes within the 
glutaminolysis pathway. Depletion of glutamine prevents the replenishment of TCA 
cycle metabolites and induces cells to undergo apoptosis. On the contrary, the 
replenishment of the mitochondrial carbon pool by glutamine provides mitochondria 
with precursors for the maintenance of mitochondrial membrane potential and for the 
synthesis of nucleotides, proteins and lipids [58], [59]. Furthermore, glutamine has 
also been described as an essential activator of the mammalian target of rapamycin 
complex 1 (mTORC1), which regulates protein translation, cell growth and autophagy 
[60]. 
 
1.3.4 Serine metabolism 
Apart from the glutamine metabolism, serine and glycine are also important mediators 
in cancer cell development. Serine and glycine are biosynthetically linked, and 
together provide essential precursors for the synthesis of proteins, nucleic acids, and 
lipids that are crucial to cancer cell growth. Serine hydroxymethyltransferase (SHMT) 
converts serine to glycine, connecting the serine and glycine pathways. Glycine is 
required to maintain the cellular redox balance and also sustains oxidative 
phosphorylation in the mitochondria [61]. It has been shown that glycine uptake and 
catabolism are able to promote tumorigenesis and malignancy, suggesting that serine 
and glycine metabolism could in principle be a target for therapeutic intervention [62]. 
Serine is an important amino acid, not only for protein synthesis, but also for other 
amino acids, lipids, as well as nucleotide biosynthesis. The endogenous serine 
synthesis pathway, is the main source of serine in several mammalian tissues, serving 
also as a source for glycine and one-carbon units for methylation (Figure 5). The 
upregulation of this pathway has been associated with the ability of breast cancer cells 
to metastasize [63]. Furthermore, a loss of function screen pointed out that certain 
breast cancers show PHGDH amplifications and rely on endogenous serine production 
to sustain proliferation [64]. Interestingly, metabolomics analysis showed that 
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melanoma and breast cancer cells with PHGDH amplification divert large amounts of 
glucose-derived carbons into serine and glycine biosynthesis [65]. 
 
Figure 5 - Serine synthesis pathway. 
Scheme of the serine synthesis pathway from glucose and the main biosynthetic pathways in 
which L-serine is involved. PHGDH, phosphoglycerate dehydrogenase; PSAT1, 3-
phosphoserine α- ketoglutarate aminotransferase; PSPH, 3-phosphoserine phosphatase; 
SHMT1/2, serine hydroxymethyl transferase 1 and 2. Dotted lines indicate multiple step 
reactions. 
 
In addition to the endogenous serine synthesis pathway, serine metabolism is also 
important for cancer cells, by contributing to redox balance and glutathione 
production. Furthermore, p53 has been related to the ability of cells to survive to serine 
starvation [66], [67]. 
 
1.3.5 The role of metabolism in cancer therapy 
The increased biosynthetic activity of rapidly proliferating cancer cells provides an 
‘Achilles heel’, as cells depend on the biosynthesis of macromolecules, such as fatty 
acids, nucleotides and amino acids. During the recent years, it has become clear that 
altered metabolism could be utilized to develop novel therapeutic approaches and to 
increase the overall survival of cancer patients. Nowadays, changes of metabolism are 
investigated in areas of biomarker discovery, patient stratification and drug discovery 
as well as personalized medicine. 
The vast majority of metabolic pathways, which are altered in cancer cells, are also 
essential for the survival of normal cells and hence are not, in principle, suitable drug 
targets. However, changes in the activity of a pathway or the presence of a specific 
enzyme isoform may allow suitable target options. Several studies demonstrate that 
the metabolic adaptations of cancer cells are not only the consequence of oncogenic 
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signaling events but can be causally involved in the transformation process. Opinions 
are emerging that selective pressure can not only alter the activity of metabolic 
enzymes to enhance the survival of cancer cells, but can also lead to the production of 
onco-metabolites that may drive tumorigenesis. 
Based on these hypotheses, new potential treatment options are emerging. In some 
tumors, oncogenic BRAF and RAS mutations have been associated with increased 
GLUT1 expression and specific GLUT1 inhibitors are currently being explored in 
clinical trials [68], [69]. Another example, addressing the increased lactate production 
of cancer cells, is the PDK inhibitor DCA (Dichloroacetate), that showed anti-cancer 
effects in pre-clinical studies and it is already a prescription drug for the treatment of 
lactic acidosis and well tolerated in patients with glioblastoma multiforme (GBM) 
[70]. However, neither DCA nor other PDK inhibitors have been approved yet for 
cancer therapy. A number of therapeutic strategies that target upstream regulators of 
metabolic pathways, like the hypoxia response factor HIF and the PI3K/AKT signaling 
cascade, are also emerging as potential targets of interest [71], [72]. 
Tumor growth is not only characterized by uncontrolled proliferation but also by 
changes in the microenvironment of the cancer cells. Moreover, the tumor 
microenvironment itself can impact tumor metabolism and affect the metabolic 
activity of cancer cells. The increased nutrient influx into cancer cells and their 
enhanced metabolic rate also leads to an increase in metabolic by-products that are 
secreted into the surrounding tissue. In order to remove any toxic by-products, tumor 
cells need profound mechanisms that can stabilize their intracellular as well as their 
extracellular environment. One of these metabolic adaptations due to changes in the 
microenvironment is represented in the metabolic rewiring in oxygen deprived 
conditions, like tumor hypoxia. 
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1.4 Tumor hypoxia 
 
1.4.1 Tumor hypoxia and microenvironment 
Tumor hypoxia is characterized as an insufficient oxygen supply for metabolic needs 
of the cell and has been shown to be an independent adverse prognostic factor in many 
cancers, including breast cancer [73]. The negative effect of tumor hypoxia on survival 
is displayed in two ways. On the one hand, limited effectiveness of radiation therapy 
leads to less oxygen free radicals generated by ionizing radiation that can cause DNA 
damage such as cross linkages and double-strand breaks [74]. On the other hand, 
hypoxic cells can be chemo resistant due to decreased drug action in the absence of 
oxygen, cell cycle changes, or altered pH gradients [75]. 
Hypoxia in solid tumors arises from changes in the tumor vasculature such that oxygen 
demands exceed supply (Figure 6). 
 
Figure 6 - The vascular network of normal tissue versus tumor tissue. 
The picture shows the vascular network of normal tissue (a) and tumor tissue (b). The Figure 
was adapted from Brown et al., 2004 [76]. AV, Arteriovenous. 
 
These abnormalities arise mainly from a rapidly growing tumor, inefficient alignment 
of capillaries, low partial pressure (pO2) in regions distant from arteriolar origin, low 
vascular density, and variations in capillary red blood cell flux [76].  
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A key factor of hypoxia is the activation of gene expression pathways to control 
angiogenesis, resistance to oxidative stress, the switch to anaerobic metabolism, 
metastasis, and to enhance survival of tumor cells after therapy [77]. Conditions of 
very severe hypoxia are commonly called anoxia and also reflect the morphology in 
tumors. In response to anoxia, cells induce cryoprotective programs and stress 
response to protect key cellular components by reducing translation, increasing 
expression of endoplasmic reticulum chaperones and arresting in G1 phase of the cell 
cycle [78]. 
Compared to room air oxygen with a pO2 of approximately 159 mmHg, the pO2 in 
arterial blood reaches approximately 40 mmHg, and most normal tissues show levels 
of above 20 mmHg. A partial pressure of less than 10 mmHg, generally induces genes 
regulated by the hypoxia-inducible transcription factor which is further discussed in 
the next section. Some normal tissues like primitive stem cells in the bone marrow are 
hypoxic per se and are maintained in a quiescent state by hypoxia-related proteins. 
Tumors show a heterogeneous picture in oxygen status and frequently display large 
hypoxic areas (in approximately 60% of solid tumors) with pO2 median values across 
the tumor of less than 10 mmHg [79]. 
Hypoxic experiments referred to in this thesis were performed at 21%, 1,2% or 0.2% 
oxygen and are roughly equivalent to pO2 of 159 mmHg, 9 mmHg and 1.5 mmHg 
respectively. 
 
1.4.2 Hypoxia-inducible factors and their role in cancer 
Hypoxia inducible transcription factor 1 (HIF-1) is a key regulator of the hypoxic 
response. HIF was discovered and first mentioned as the transcriptional regulator of 
the erythropoietin gene (EPO) in renal fibroblasts and HIF activation under low 
oxygen concentrations was found to lead to an increased EPO production [80]. There 
are three genes that encode α-subunits of HIF in mammals (HIF-1α, HIF-2α and HIF-
3α). HIF-1 consists of two subunits, α (inducible) and β (constitutively-expressed, or 
ARNT). 
In the presence of oxygen, proline residues in the oxygen-dependent degradation 
domain of HIF-1α are hydroxylated by prolyl hydroxylases (PHDs) [81]. This enables 
the von Hippel-Lindau (VHL) protein to recognize HIF-1α, causing it to be 
ubiquitylated and targeted to the proteasome for degradation [82]. The process is 
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precisely regulated in several ways, including cofactor dependencies of the PHDs such 
as ascorbate (Vitamin C), Krebs cycle intermediates, and iron [83]. 
In oxygen-deprived tissues (below 2% O2), HIF α-subunits become stabilized and 
consequently activated due to the diminished activity of the prolyl hydroxylases 
(PHDs) and hetero-dimerize with ARNT. These heterodimers recognize and bind to 
hypoxia response elements (HRE) (5'-[AG]CGTG-3'), specific genomic sequences 
that lie within target gene promoters and recruit transcriptional co-activators such as 
p300/CBP for full transcriptional activity (Figure 7). This leads to changes in the 
transcription of genes that are necessary to overcome oxygen deprivation [80]. HIF-
1α activation helps cells to adapt to oxygen deprivation by regulating the expression 
of genes involved in proliferation, metabolism, angiogenesis and invasion/metastasis 
[84]. 
 
Figure 7 - HIF-1α structure and its regulation. 
The HIF-1α cascade and its fate under normoxic and hypoxic conditions. The Figure was 
adapted from Weidemann et al., 2008 [82]. 
 
Historically, most research has been centered around HIF-1α, but more recently 
specific targets and roles of HIF-2α have become well understood. Hypoxia inducible 
transcription factor 2α (HIF-2α) is a protein with sequence similarity to HIF-1α, also 
regulated by proline hydroxylation. HIF- 2α activates transcription of a group of target 
genes that overlap with, but are distinct from those regulated by HIF-1α [85], [86]. For 
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example, opposing effects of HIF-1α and HIF-2α on the activity of c-Myc have been 
reported [87]. Furthermore, there is evidence that HIF-1α is more important for 
metabolic regulation in cancer cells, while HIF-2α is thought to mainly act on the 
regulation of angiogenic and metastatic processes [88]. In contrast to the presented 
transcription factors, the HIF-3α is an inhibitor of HIF-1α that is rarely studied and is 
thought to be involved in feedback regulation [89]. 
The activity of HIF-1α is controlled on several levels and various studies have shown 
elevated levels of HIF-1α and/or HIF-2α in primary tumors and their metastases [90], 
[91]. Oncogenic pathways can stabilize HIF-1α, of which the best described are the 
RAS and the PI3K/Akt pathways [92]. Additionally, growth factors such as HER2, 
especially when upregulated, can also increase HIF-1α synthesis, primarily via the 
action of mammalian target of rapamycin (mTOR). The balance of these pathways is 
critical for tumor growth and development [93]. Furthermore, fluctuations in hypoxia 
typically seen in tumors, has been shown to generate a higher level of stabilized HIF-
1α than a stable hypoxia exposure [94]. HIF-1α activates multiple hypoxia-response 
genes with roles in many aspects of cancer biology, including angiogenesis, immune 
evasion, pH regulation, glycolysis, invasion and metastasis [95], [96], [97], [98], [99]. 
Thus, HIF-1α induces a number of genes which enable cells to adapt to low oxygen 
condition, and thereby contribute to cancer progression. The elevation of HIF-1α and 
HIF-2α expression levels is associated with increased tumor growth and poor 
prognosis in the majority of human tumors including breast cancer [100]. 
 
1.4.3 Limitations of existing hypoxia markers 
Tumor cells exhibit a distinct growth pattern into surrounding healthy tissue 
accompanied by limited access to the vascular system for certain areas of the tumor. 
This also leads to heterogenic features in hypoxic regions. These hypoxic regions 
correlate with increased HIF-1α and HIF-2α levels and have been associated with a 
poor OS signature in several cancers like brain, pancreas, colon and breast [101]. 
Assessing hypoxia in tumors is a complicated matter since current methods have 
significant limitations. Measuring pO2 directly via polarographic needle electrodes is 
invasive and provides no information about the hypoxic distribution across the whole 
tumor architecture [102]. Nuclear medicine imaging and radiological techniques can 
provide suitable data but are expensive, suffer from low resolution and are hard to 
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standardize between many centers. In addition, the markers used are mainly dependent 
on the glycolytic state of the cell [103]. 
Another way to assess hypoxia may be through the expression of many hypoxia-
induced genes, like the median RNA expression signature of a 99-gene set predicting 
recurrence-free survival in head and neck cancer [104]. Similarly, a gene-expression 
signature of the cellular response to hypoxia was developed for prognosis in ovarian 
and breast cancer [105]. 
Therapeutic drugs in the hypoxic context, like Bevacizumab, a monoclonal antibody 
targeting VEGFA, have shown some promising effects in certain cancers such as renal 
cancer and metastatic colorectal cancer. However, in other entities such as breast 
cancer the patient benefits were rather disappointing. It has been demonstrated that 
hypoxic breast tumors do no respond well to established therapeutics and 
predominantly show poorer clinical outcome [106]. Identifying novel targets within 
these hypoxic tumors is a necessary need and a worthwhile endeavor. 
Along this line, most studies lack novelty and translation into the proteomic level. 
Therefore, a part of my PhD project aimed to address this issue and to investigate a 
new hallmark of cancer in the context of hypoxia at a proteomic level via reverse phase 
protein arrays. 
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1.5 Reverse phase protein arrays 
 
1.5.1 The RPPA technology 
The Reverse Phase Protein Array (RPPA) technology represents a highly efficient and 
cost effective successor of miniaturized immunoassays that use a sandwich format for 
antigen capture [107], [108]. First described by Paweletz et al. in 2001, the term 
“reverse phase” refers to the analytes (antigen) which are immobilized on a solid phase 
(nitrocellulose), and subsequently probed with an antibody against a specific target 
[109]. RPPA allows to multiplex quantitative measurements of total, phosphorylated, 
glycosylated, acetylated or cleaved proteins from multiple samples [110]. The 
technology is widely used for protein expression profiling and signal pathway mapping 
in cell lines, clinical specimen, as well as serum and plasma samples [111], [112], 
[113], [114]. The basic readout is usually reflected in the detection of a unique change 
in expression of one protein, or pattern of changes in many proteins as well as protein 
networks (Figure 8). 
 
 
Figure 8 - The basic principle of RPPA. 
Reverse phase protein arrays (RPPA) experimentation involves (A) printing of samples in a 
neatly organized array format onto, for example, nitrocellulose-coated glass slides; (B) 
Incubation with a highly target-specific primary antibody to detect proteins-of-interest, or a 
certain phosphorylation sites; (C) Signal detection of the primary antibody is commonly 
performed by fluorescence, chemiluminescence or colorimetric methods; (D) Target intensities 
are quantified after scanning and analyzing signal intensities of individual spots; (E) Data 
processing and quality control. NIR, Near-infrared. 
 
During the last decade, the RPPA approach has been used for several applications in 
the field of system biology and biomarker discovery in different tumor entities [115], 
[116]. RPPA has been shown to be able to concurrently measure a large number of 
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analytes with an analytical precision and accuracy similar or superior to clinical-grade 
assays such as ELISAs [114]. Especially the high throughput capabilities and 
sensitivity of RPPA paved the way for in depth investigations of tissue samples, 
usually originating from small-bore core biopsies or fine needle aspirates, with 
exceedingly small amounts of target material. Unlike other existing competing 
technologies, RPPA can quantitatively measure large numbers of low abundance 
analytes, such as phosphorylated signaling proteins, from a single small sample input 
[117]. Several studies could show, that this technology can generate linear quantitative 
data with an analytical sensitivity of detection in the fg/ml range with linearity in the 
sub pg/ml range, which is several orders of magnitude more sensitive compared to 
current multiple reaction monitoring (MRM) mass spectrometry approaches [118], 
[119], [120]. In addition, the throughput of RPPA is currently not feasible by 
conventional western blot or any other proteomic technology. 
Taken together, RPPA represents a rapidly emerging and advancing cost-effective 
technology that is able to quantitatively analyze hundreds of proteins and post-
translational modifications in small samples sizes. While other proteomic approaches 
like mass spectroscopy hold great promise for the analysis of samples, they do not 
currently have the throughput, sensitivity and ability to deal with small amounts of 
material, or the cost effectiveness of the RPPA platform [121]. 
 
1.5.2 RPPA platform at DKFZ 
The RPPA platform at the Division of Molecular Genome Analysis (DKFZ) was 
established in 2007 and further developed in terms of automation and data processing 
in the recent years [122], [123], [124]. The general principle of the RPPA platform at 
DKFZ is outlined in Figure 9 and a detailed workflow description can be found in 
Chapter 3, Section 3.2.7. The flexibility of the RPPA technology to analyze large 
sample numbers in parallel either in an unbiased approach or for a protein network of 
choice, remains the major strength of the platform and provides the opportunity to 
study hundreds of patient samples simultaneously. Based on these core attributes that 
favor biomarker guided clinical research and the ability to identify therapeutic markers 
that could be suitable for patient stratification, I used the RPPA platform as the method 
of choice for my PhD project. 
Introduction 
27 
 
 
Figure 9 - RPPA workflow at DKFZ. 
Schematic presentation of the DKFZ workflow of using reverse phase protein arrays for a 
targeted profiling. NC, Nitrocellulose; NIR, Near-infrared. 
 
The reliability of RPPA highly depends on the quality of the antibodies used. However, 
universally applied guidelines or a standardized workflow for determining the 
antibodies applicable for use in RPPA has not yet been established. Antibody 
validation during my PhD was carried out as previously described [125]. Primary 
antibodies were selected in order to cover a range of metabolic pathways and to 
achieve a broad perspective on breast cancer metabolism. Please refer to Chapter 3, 
Section 3.1.5 for further information on antibodies relevant to this project. 
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Breast cancer tumors are highly heterogeneous and differences in their metabolic 
phenotypes are not well understood. While a number of mostly RNA-based profiling 
studies have aimed at improving diagnosis and therapy decision, few tests have entered 
clinical practice. Furthermore, less is known about the metabolic phenotype of breast 
cancer, especially on a proteomic scale. Currently there are no studies that have 
systematically examined the prognostic value of metabolism associated enzymes in a 
large cohort of breast cancer patients or investigated the dynamic behavior of 
microenvironmental factors like hypoxia on cancer metabolism in a time resolved 
manner. 
 
In order to provide novel insides into the proteomic landscape of breast cancer, I 
addressed the following questions: 
 
Is a targeted proteomic approach applicable towards the characterization of breast 
tumors at the metabolic level? 
• A large cohort of breast tumor specimen was utilized via targeted 
proteomics and further statistically examined for metabolic features. 
 
Which metabolic enzymes, transporters and regulators are important for the survival 
of breast cancer patients and could serve as potential biomarkers? 
• Based on the generated protein expression matrix, the relationship 
between metabolism-associated protein expression profiles and 
clinicopathological characteristics were evaluated. 
 
What are the metabolic adaptive responses under hypoxia and its main regulators? 
• Time resolved breast cancer cell line data was generated via targeted 
proteomics and further processed by bioinformatic methods. Findings 
were assessed in order to reveal metabolic changes, with a focus on top 
regulated targets. 
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3.1 Materials 
 
3.1.1 Patient cohort and clinical samples 
Human primary breast cancer samples were collected at the Martin-Luther University, 
Halle-Wittenberg between 2009 and 2011 as part of the multicenter prospective PiA 
trial (NCT 01592825). Only fresh frozen tissue samples of female patients with 
operable non-metastasized breast cancer were included. The study was approved by 
the ethics committee of the Martin-Luther University Halle-Wittenberg and informed 
consent had been obtained from each patient. I investigated a cohort of 801 primary 
tumor tissue samples with RPPA. Tumor specimens were fresh frozen after surgery 
and stored at −80 °C until further use. Tumor content was verified by histopathology. 
Clinicopathological parameters were obtained for each patient and documented using 
SPSS 22. TNM staging system was used [126]. Patient information was anonymized 
prior to analysis. Receptor defined breast cancer subtypes were determined according 
to the St. Gallen classification [12]. Due to missing Ki-67 values, histopathological 
grading was used to assess cell proliferation [127]. The standardized definitions for 
efficacy end points (STEEP) criteria were used as endpoint definitions [128]. 
 
The following stratification system was applied: 
 
Luminal A-like:  Estrogen receptor (ER) positive and/or Progesterone receptor 
(PgR) positive, HER2 negative, grade 1 or 2. 
Luminal B-like:  ER positive and/or PgR positive, HER2 negative, grade 3. 
(HER2 negative) 
Luminal B-like:  ER positive and/or PgR positive, HER2 positive, all grades. 
(HER2 positive) 
HER2 positive:  ER negative and PgR negative, HER2 positive, all grades. 
(non-luminal-like) 
Triple negative:  ER negative, PgR negative, HER2 negative, all grades. 
(TNBC) 
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3.1.2 Instruments 
Aushon 2470 contact printer Aushon BioSystems (Billerica, US) 
BINDER Cell culture incubator BINDER GmbH (Tuttlingen, DE) 
Biofuge fresco centrifuge Heraeus (Hanau, DE) 
Biohit Proline multichannel pipette Sartorius (Göttingen, DE) 
BP121S and BP2100S balances Sartorius (Göttingen, DE) 
CASY cell counter Roche Innovatis AG (Bielefeld, DE) 
Dri-block®DB-2D heating block Bibby Scientific Limited (Stone, UK) 
DURAN® desiccator Schott (Mainz, DE) 
ErgoOne® pipette Starlab International (Hamburg, DE) 
HERA Safe cell culture hood Thermo Fisher Scientific (Waltham, 
US) 
Infinite M200 microplate reader Tecan Group (Männedorf, CH) 
inoLab pH meter WTW (Weilheim, DE) 
Liebherr Premium Freezer Liebherr-International (Biberach an der 
Riß, DE) 
Liebherr Premium Fridge Liebherr-International (Biberach an der 
Riß, DE) 
Milli-Q Biocel purification system Merck Millipore (Darmstadt, DE) 
Mini-Protean®II electrophoresis cell 
system 
BioRad (München, DE) 
Microscope IXM XL Molecular Devices (Sunnyvale, US) 
MR3001 magnetic stirrer Heidolph (Schwabach, DE) 
Multipette®plus hand-held dispenser Eppendorf AG (Hamburg, DE) 
Odyssey® Infrared Imaging System LI-COR Biosciences (Lincoln, US) 
Pipetboy acu pipette INTEGRA Biosciences (Fernwald, DE) 
Pipetman® pipette Gilson (Limburg, DE) 
Thermomixer comfort Eppendorf AG (Hamburg, DE) 
TissueLyser bead mill Qiagen (Hilden, DE) 
Titramax 100 rocking platform Heidolph (Schwabach, DE) 
Trans-Blot® Turbo™ Transfer System BioRad (München, DE) 
Tube Rotator VWR (Darmstadt, DE) 
Vacuboy aspiration device INTEGRA Biosciences (Fernwald, DE) 
VortexMixer 7-2020 neoLab (Heidelberg, DE) 
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3.1.3 Consumables 
348-well plate, AB-1056 Abgene (Epsom, UK) 
1.5 mL micro centrifuge tube  Eppendorf AG (Hamburg, DE) 
10cm Ø Petri dish Techno Plastic Products (TPP) AG 
(Trasadingen, CH) 
15mL conical tube Becton Dickinson (New Jersey, US) 
2 mL micro centrifuge tube Eppendorf AG (Hamburg, DE) 
50mL conical tube Becton Dickinson (New Jersey, US) 
6-well plate Nunc, Thermo Fisher Scientific 
(Waltham, US) 
96-well plate Becton Dickinson (New Jersey, US) 
Adhesive Optically Clear Plate Seal Thermo Fisher Scientific (Waltham, 
US) 
Anaeroclip® Merck KGaA (Darmstadt, DE) 
Anaerotest® Merck KGaA (Darmstadt, DE) 
Casy cup Roche Innovatis AG (Bielefeld, DE) 
Cell Culture Flasks, T-25, T-75, T-175 Greiner Bio-One International GmbH 
(Kremsmünster, AT) 
Cell Scraper Corning (Corning, US) 
Combitip Eppendorf AG (Hamburg, DE) 
Cry vials 1.8mL Nunc, Thermo Fisher Scientific 
(Waltham, US) 
Desiccant bag Conrad Electronics (Hirschau, DE) 
Filter tips, 10μL, 20μL, 100μL, 200μL, 
1000μL 
Neptune Scientific (San Diego, US) 
Mini-PROTEAN® TGX™ Precast Gel BioRad (München, DE) 
Oncyte® Avid Nitrocellulose Film-Slide Grace Bio-Labs (Bend, US) 
pipette tip Becton Dickinson (Heidelberg, DE) 
Scalpel Feather No21 pfm medical (Köln, DE) 
Serological pipettes 2.5mL, 5mL, 10mL, 
25mL, 50ml 
Becton Dickinson (New Jersey, US) 
Stainless steel bead (5 mm) Qiagen (Hilden, DE) 
Trans-Blot® Turbo™ LF PVDF 
membrane 
BioRad (München, DE) 
Trans-Blot® Turbo™ Transfer Stacks BioRad (München, DE) 
Whatman paper GE Healthcare (München, DE) 
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3.1.4 Chemicals and reagents 
CASYton Roche Innovatis AG (Bielefeld, DE) 
cOmplete Mini Protease Inhibitor 
Cocktail 
Roche Diagnostics (Mannheim, DE) 
EDTA Sigma-Aldrich (Saint-Louis, US) 
Ethanol Sigma-Aldrich (Saint-Louis, US) 
Fast Green FCF Carl Roth (Karlsruhe, DE) 
KCL Sigma-Aldrich (Saint-Louis, US) 
Methanol Greiner Bio-One International GmbH 
(Kremsmünster, AT) 
M-PER mammalian protein extraction 
reagent 
Thermo Fischer Scientific (Rockford, 
US) 
NaCl VWR International (Darmstadt, DE) 
NaOH Sigma-Aldrich (Saint-Louis, US) 
peqGOLD Protein Marker IV and V PEQLAB Biotechnologie (Erlangen, 
DE) 
PhosSTOP Phosphatase Inhibitor 
Cocktail 
Roche Diagnostics (Mannheim, DE) 
Rockland Blocking Buffer Rockland Immunochemicals Inc. 
(Limerick, US) 
Roti®-Load 1, 4x sample loading buffer Carl Roth (Karlsruhe, DE) 
Staurosporine Merck Millipore (Darmstadt, DE) 
SDS Carl Roth (Karlsruhe, DE) 
Trans-Blot® Turbo™ Transfer Buffer BioRad (München, DE) 
Tris HCl Sigma-Aldrich (Saint-Louis, US) 
Tris-base Sigma-Aldrich (Saint-Louis, US) 
Triton X-100 Sigma-Aldrich (Saint-Louis, US) 
Tween 20 Sigma-Aldrich (Saint-Louis, US) 
 
3.1.5 Antibodies 
Primary Antibodies 
Dataset ID Gene ID Catalog# Company 
ACC ACACA 3662 Cell Signaling Technology (US) 
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Dataset ID Gene ID Catalog# Company 
ACC_Ser79 ACACA 3661 Cell Signaling Technology (US) 
ARG2 ARG2 GTX118048 GeneTex (US) 
ASCT2 SLC1A5 8057 Cell Signaling Technology (US) 
ASL ASL HPA016646 Sigma-Aldrich (US) 
ASS1 ASS1 HPA020896  Sigma-Aldrich (US) 
CAD CAD 11933 Cell Signaling Technology (US) 
CPS1 CPS1 ab128942 Abcam plc (UK) 
ER alpha ER E1678C002 DCS (DE) 
FASN FASN ab128856 Abcam plc (UK) 
FH FH sc100743 Santa Cruz Biotechnology (US) 
GAPDH GAPDH GTX 627408 GeneTex (US) 
GLK GCK GTX111517 GeneTex (US) 
GLS GLS ab156876 Abcam plc (UK) 
Glud12 GLUD 12793 Cell Signaling Technology (US) 
GLUL GLUL WH0002752M1 Sigma-Aldrich (US) 
GLUT1 SLC2A1 ab115730 Abcam plc (UK) 
GLUT4 SLC2A4 2213 Cell Signaling Technology (US) 
GOT1 GOT1 ab170950 Abcam plc (UK) 
GPT2 GPT2 sc398383 Santa Cruz Biotechnology (US) 
HER2 ERBB2 AB17MS730 Thermo Fisher Scientific (US) 
Hif1_alpha HIF1A 10006421 Cayman Chemical (US) 
Hif2_alpha HIF2A 7096 Cell Signaling Technology (US) 
IDH1 IDH1 8137 Cell Signaling Technology (US) 
IDH2 IDH2 12652 Cell Signaling Technology (US) 
Ki67 MKI67 M7240 Dako (US) 
LAT1 SLC7A5 5347 Cell Signaling Technology (US) 
LDHA LDHA 3582 Cell Signaling Technology (US) 
LDHB LDHB MAB2732 Abnova (TW) 
NAGS NAGS AV51183 Sigma-Aldrich Co. (US) 
ODC1 ODC1 ab126590 Abcam plc (UK) 
PCK1 PCK1 12940 Cell Signaling Technology (US) 
PCK2 PCK2 sc32879 Santa Cruz Biotechnology (US) 
PDH PDHA1 3205 Cell Signaling Technology (US) 
PGR PGR 1483 Epitomics (US) 
PHGDH PHGDH 13428 Cell Signaling Technology (US) 
PKM1 PKM1 7067 Cell Signaling Technology (US) 
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Dataset ID Gene ID Catalog# Company 
PKM2 PKM2 4053 Cell Signaling Technology (US) 
PSAT1 PSAT1 GTX110576 GeneTex (US) 
PSPH PSPH HPA020376 Sigma-Aldrich Co. (US) 
SDHA SDHA sc59687 Santa Cruz Biotechnology (US) 
SHMT2 SHMT2 HPA020543  Sigma-Aldrich Co. (US) 
SLC14A1 SLC14A1 ab67595 Abcam plc (UK) 
SMS SMS GTX114783 GeneTex (US) 
SREBP1 SREBF1 NB100-74542 Novus Biologicals, Inc. (US) 
STARD10 STARD10 HPA026661 Sigma-Aldrich Co. (US) 
 
Secondary Antibodies 
Format Reactivity Conjugate Company 
full-length IgG rabbit IgG (H+L) Alexa Flour® 680 Life Technologies (US) 
full-length IgG mouse IgG (H+L) Alexa Flour® 680 Life Technologies (US) 
F(ab')2 rabbit IgG (H+L) Alexa Flour® 680 Life Technologies (US) 
F(ab')2 mouse IgG (H+L) Alexa Flour® 680 Life Technologies (US) 
 
3.1.6 Buffers and solutions 
10x TBS: 1.37 M NaCl 
200 mM Tris 
pH 7.6 
10x TBST: 0.1% Tween20® in 10x TBS 
Cell line lysis buffer: mammalian protein extraction reagent (M-PER) 
1 tablet PhosSTOP Phosphatase Inhibitor Cocktail 
1 tablet Complete Mini Protease Inhibitor 
Cocktail 
Tissue lysis buffer: 50 mM Tris, pH 8.5 
138 mM NaCl 
2.7 mM KCl 
1% Triton X-100 
SDS-PAGE running buffer: 192 mM glycine 
25 mM Tris 
0.1% SDS 
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Transfer buffer 1L: 20% Trans-Blot® Turbo™ 5x Transfer Buffer 
20% EtOH 
60% H2O 
Blocking buffer: 50% Rockland blocking buffer 
5 mM NaF 
1 mM Na3VO4 
ad TBS 
Washing buffer: 0.1% Tween®20 in TBS (TBST) 
4x RPPA printing buffer: 10% Glycerol 
4% SDS 
10 mM DTT 
125 mM Tris 
pH 6.8 
FCF staining solution: 0.005% Fast Green FCF 
10% acetic acid 
30% ethanol 
FCF destaining solution: 10% acetic acid 
30% ethanol 
 
3.1.7 Kits 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific (Waltham, 
US)  
Anaerocult® A mini Merck KGaA (Darmstadt, DE) 
Trans-Blot® Turbo™ RTA Transfer Kit BioRad (München, DE) 
 
3.1.8 Cell culture 
Breast cancer cell lines were purchased from the American Type Culture Collection 
ATCC (LGC Standards GmbH, Wesel, DE). Cell line authentication was performed 
via multiplex cell line authentication (Multiplexion GmbH, Friedrichshafen, DE). 
 
Cell line Characteristics 
MCF-7 ER+, HER2-, epithelial-like, adenocarcinoma from 
pleural effusion 
SKBR3 ER-, HER2+ (amplified), epithelial-like, adenocarcinoma 
from pleural effusion 
MDA-MB-231 ER-, HER2-, epithelial-like adenocarcinoma from pleural 
effusion 
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MDA-MB-468 ER-, HER2-, epithelial-like, adenocarcinoma from pleural 
effusion 
 
Media and reagents used for cell culture 
0.25% Trypsin EDTA (1x) Gibco BRL (New York, US) 
Fetal Bovine Serum Gibco BRL (New York, US) 
RPMI 1640 (+ L-Glutamine) Gibco BRL (New York, US) 
RPMI 1640 (- L-Glutamine) Gibco BRL (New York, US) 
Dulbecco's Phosphate Buffered Saline Gibco BRL (New York, US) 
 
3.1.9 Software 
GenePix Pro 7.0 Molecular Devices (Sunnyvale, US) 
GraphPad Prism 5 GraphPad Software Inc. (La Jolla, US) 
Molecular Devices MetaXpress Molecular Devices (Sunnyvale, US) 
Odyssey 3.1 LI-COR Biosciences (Lincoln, US) 
R version 3.0.2 
 
SPSS 22 
R Development Core Team  
(www.R-project.org) 
SPSS Inc. (Illinois, US) 
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3.2 Methods 
 
3.2.1 Preparation of protein extracts from cell lines 
Cells were lysed on ice with pre-chilled cell line lysis buffer (M-PER lysis buffer 
containing protease inhibitor Complete Mini and anti-phosphatase PhosSTOP). Cell 
lysates were incubated on a tube rotator for 30 min at 4°C and subsequently centrifuged 
for 10 min at 16.000 x g. Supernatant was stored at -80°C until further use. Total 
protein concentration was quantified with Pierce™ BCA Protein Assay Kit according 
to manufacturer’s instructions. 
 
3.2.2 Preparation of protein extracts from tumor samples 
Frozen tumor specimens were homogenized using a bead mill and pre-chilled tissue 
protein extraction reagent (50 mM Tris, pH 8.5, 138 mM NaCl, 2.7 mM KCl, 1% 
Triton X-100). Tumor lysates were centrifuged at 16.000 x g for 10 min at 4°C. The 
homogenized tumor lysate supernatants were aliquoted and stored at -80°C until 
further use. Total protein concentration was quantified with Pierce™ BCA Protein 
Assay Kit according to manufacturer’s instructions. 
 
3.2.3 Immunoblotting 
Protein lysates were denatured using 4x sample loading buffer (Roti®-Load 1) for 5min 
at 95°C. Samples were loaded on Mini-PROTEAN® TGX™ Precast Gels for protein 
mass separation and a prestained protein ladder (peqGOLD Protein Marker IV and V) 
was used as molecular mass marker. After protein separation via SDS-PAGE, the 
proteins were transferred to a polyvinylidene difluoride membrane (Trans-Blot® 
Turbo™ LF PVDF membrane) by electrophoresis. The Trans-Blot® Turbo™ Transfer 
System was used for the “semi dry” blotting set-up in accordance to the manufacture 
instructions. Afterwards the membrane was blocked for 1h at RT with blocking buffer 
and subsequently incubated with target specific primary antibody over night at 4°C on 
a rocking platform. The membrane was washed 4 x 5 min in TBST followed by an 1h 
incubation with Alexa Flour® 680 conjugated secondary antibody. After washing for 
4 x 5 min, the membrane was scanned at an excitation wavelength of 685 nm and a 
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resolution of 84 µm using the Odyssey® Infrared Imaging System. For western blot 
quantification, local background subtraction and β-Actin normalization was 
performed. 
 
3.2.4 Antibody validation 
Each antibody was tested for specificity to assure the detected signal is representative 
for the target of interest. The gold standard for antibody validation is western blot. A 
pool of different breast cancer cell lines was used as test samples. All antibodies 
resulting in a target specific single band or characteristic band pattern were used for 
RPPA. Antibodies resulting in several unspecific bands were not used for RPPA. All 
Antibodies used for RPPA profiling are provided in Chapter 3, Section 3.1.5. 
 
3.2.5 Immunohistochemistry 
Immunohistochemistry (IHC) analyses were performed by PD Dr. med. Jörg 
Buchmann at the pathology department of the Martin-Luther University Halle-
Wittenberg on 4-micron tissue sections. Protein expression was assessed using Bond 
Max Polymer Refine Immunohistochemistry protocol. Primary SHMT2 and ASCT2 
antibody was diluted 1:250. Epitope retrieval was performed with Bond Epitope 
Retrieval Solution for 30 minutes at pH6, followed by a peroxidase block. Primary 
antibody was incubated for 20 minutes and detected using Bond Polymer Refine 
Detection with DAB substrate. IHC were assessed by a pathologist as a visual score, 
semi-quantitative based on the fraction of cytoplasmic staining above background. 
 
3.2.6 Hypoxia exposure 
Exposure of cell cultures to hypoxia (1,2% or 0.2% oxygen) was undertaken in a cell 
culture incubator at 1.2% oxygen or in hypoxia bags at 0.2% oxygen (Anaerocult® A 
mini). In parallel, cells were maintained in normoxic conditions (5% CO2, 37°C, 21% 
oxygen). All experiments were performed in triplicate from independent cell cultures. 
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3.2.7 Reverse phase protein arrays 
Tumor and cell line lysates were adjusted to a total protein concentration of 2 µg/µl. 
Samples were mixed with 4 x RPPA printing buffer (10% glycerol, 4% SDS, 10 mM 
DTT, 125 mM Tris–HCl, pH 6.8) and denatured at 95°C for 5 min. Protein lysates 
were transferred to 348-well plates and centrifuged for 2 min at 200 x g. Six step 
dilution series of tumor samples/cell line pools were serving as internal controls. All 
samples were printed as technical triplicates on Oncyte® Avid Nitrocellulose Film-
Slides using a Aushon 2470 contact printer equipped with 185 µm solid pins (1.6 nl 
sample per spot, average spot diameter 250 µm). The humidity during the printing run 
was kept constant at 80%. Slides were stored after the print run at -20°C with desiccant. 
Post spotting, slides were incubated with blocking buffer in TBS (50%, v / v) 
containing 5 mM NaF and 1 mM Na3VO4 for 2h at room temperature. Each array was 
subsequently incubated with target-specific primary antibodies at 4°C overnight. 
Representative subarrays were incubated without primary antibody and served as 
“blank” control. After performing washing steps with 4 x 5 min TBST the detection 
of primary antibodies was carried out with Alexa Fluor® 680 F(ab')2 fragments of goat 
anti-mouse IgG or anti-rabbit IgG in 1:12000 dilution for 1h at RT. Slides were washed 
4 x 5 min with TBST followed by two final washing steps with ultra-pure water for 5 
min. Slides were air dried and further utilized in the imaging process. All incubation 
and washing steps were performed on a rocking platform and slides were protected 
from light. Every ninth slide of each run was stained using Fast Green FCF protein dye 
for total protein quantification and served as normalization reference. TIFF images (16 
bit) of all slides were obtained at an excitation wavelength of 685 nm and a resolution 
of 21 μm using the Odyssey® Infrared Imaging System. 
Signal intensities of individual spots were quantified using GenePixPro 7.0 software. 
The aquirred TIFF image of each slide and gene pix array list file, generated by the 
printer to map the sample location on the slide, were matched into a gene pix result 
file. At this step, a visual inspection of each spot was performed and slides without 
uniform background signal were excluded from further analysis. RPPA raw data 
preprocessing and quality control were performed using the RPPanalyzer R-package 
[123]. The gene pix result files as well as sample and antibody information text files 
were required for further raw data analysis. The raw signal intensities of the control 
samples were plotted against the respective total protein concentration. Only data of 
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antibodies showing a linear correlation between target signal intensity and protein 
concentration were used for further analysis. Next, target signals were normalized to 
the total protein amount per spot via Fast Green FCF control. After median calculation 
of technical replicates, normalized target signal intensities were plotted against the 
signal intensities obtained by incubation of primary antibody controls (blank signal). 
Normalized protein data was saved in text files and further explored in collaboration 
with our collaboration partners at the Department of Medical Statistics at University 
Medical Center Goettingen (Goettingen, Germany) and the Institute of Physics at the 
Freiburg Institute for Advanced Studies (Freiburg, Germany). 
 
3.2.8 Statistical and bioinformatic analyses 
If not stated otherwise, the data was analyzed using GraphPad Prism 5 or the R 
statistical computing environment (version 3.0.2) [129]. A p value < 0.05 was 
considered statistically significant. 
 
STRING visualization 
STRING Database (Version 10) of the STRING Consortium was used for visualization 
of protein interactions by choosing Gene IDs corresponding to proteins [130]. 
 
Hierarchical clustering 
Hierarchical cluster analysis was performed on z-scores of protein expression levels 
using Ward's minimum variance method and squared euclidean distance. Patient 
samples and protein targets were clustered simultaneously and the resulting 
dendrograms were visualized together with a heatmap depicting z-score values. 
RPPanalyzer R-package was used for visualization, with an adjustment of color bars 
according to the clinicopathological features of interest and exploiting the dendextend 
R-package for dendrogram color-coding [123], [131]. 
 
Univariate analysis 
The relationship between clinicopathological variables and the three patient clusters 
was evaluated using analysis of variance (ANOVA), Kruskal-Wallis rank sum test, 
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and Fisher's Exact test, as appropriate. The relationship between the variables and the 
patient groups, stratified based on the median expression of a protein, was evaluated 
using t-test, Wilcoxon rank sum test, and Fisher's Exact test, as appropriate. 
 
Multivariate and survival analysis 
Patients stratified into groups (based on receptor-defined subtypes, median expression 
level or patient dendrogram clusters) were subjected to Kaplan-Meier analysis of 
overall survival (OS) and recurrence-free survival (RFS). The difference of Kaplan-
Meier curves was tested using the log-rank test implemented in the survival R-package 
[132]. Univariate Cox proportional hazard regression models were applied to test 
individual protein target association with OS and RFS [133]. For each target, the 
exponent of the estimated regression coefficient is reported as a hazard ratio (HR) 
along with its 95% confidence intervals (CI). P values were adjusted for multiple 
testing resulting in false-discovery rate (FDR) values [134]. Univariate Cox 
proportional hazard regression models were further used to evaluate 
clinicopathological variables. Multivariate Cox analyses were then performed on 
selected non-correlated clinicopathological covariates for each of the proteins that 
showed significance in the univariate Cox analysis. The median follow-up time of the 
cohort was 55.44 months for OS and 54.46 months for RFS. 
 
Linear regression model 
The preprocessed data of the time courses with triple replicates for each time point 
were analyzed individually for each target protein and for each of the 12 combinations 
of cell lines and treatments. In order to merge the replicates and asses the kind and 
strength of regulation, a linear regression model was used for the log2(10) signal 
intensities of the target protein time courses and cell line-treatment combination 
individually. The Cook's distance  was used to detect outliers in the measured time 
course [135] [136]. Based on this, 1% of data points was removed from the further 
analysis. A one-way analysis of variance (ANOVA) was applied to each time course 
in order to discriminate between a constant time course signal at the basal expression 
level of the target protein and significantly regulated expression profiles (pANOVA < 
0.05). Using t-statistics, time point specific regulation estimates have been tested 
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individually against the respective basal expression estimate in order to identify 
significantly regulated signals (p < 0.05). P-values are FDR adjusted for multiple 
testing using the Benjamini-Hochberg procedure. 
 
TCGA data analysis 
Analyses of The Cancer Genome Atlas (TCGA) data was conducted on primary breast 
cancer tumor samples with both RNA-sequencing data and clinical annotations. Level 
3 normalized gene expression data (TCGA_BRCA_exp_HiSeqV2-2015-02-24) was 
obtained from the cBioPortal website [137], [138]. Gene expression data was log2 
transformed and subset to the genes of interest. 
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4.1 Proteomic profiling of cancer metabolism in breast cancer 
patients 
 
4.1.1 RPPA patient dataset generation 
In order to investigate altered expression patterns of metabolism related proteins in the 
tumorigenesis of breast cancer, I established a collaboration with the gynecology 
department of the university clinic at the Martin-Luther-University Halle-Wittenberg 
(Halle(Saale), DE). With the aim to generate a proteomic dataset of breast cancer 
specimens, Dr. Eva Kantelhardt and Dr. Martina Vetter kindly provided me with over 
800 breast cancer samples of patients, diagnosed with primary breast carcinoma, for 
my research. The specimens received are part of an ongoing clinical trial and further 
information on clinicopathological features of the cohort are summarized in Table 2 
and in Chapter 3, Section 3.1.1. 
In a first step, the tumor specimens were lysed as described in Chapter 3, Section 3.2.2 
and I further determined the protein concentration of each sample. Afterwards I 
processed the samples via reverse phase protein arrays and produced protein array 
slides primed for primary antibody incubation. 37 suitable protein targets with 
relevance to cancer metabolism were chosen and conscientious antibody validation 
was performed. The RPPA slides were then incubated with the validated antibodies 
and a quantitative analysis of protein expression was performed. The RPPA protocol 
is reported in Chapter 3, Section 3.2.7. After quality control of the raw RPPA data 
from my side, the data matrix was further explored in collaboration with Dr. Astrid 
Wachter and Dr. Michaela Bayerlová of the Department of Medical Statistics, 
University Medical Center Goettingen (Goettingen, DE). The whole RPPA data matrix 
matched with clinical data is provided in the Appendix (Table S5). 
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Table 2 - Patient and tumor characteristics 
  Total (%) 
Number of patient samples   
        Total 801 (100) 
Age   
        Mean ± SD 62.25 ± 13.7  
        Median (range) 63 (22-90)  
Tumor size   
        < 2cm 400 (49.9) 
        ≥ 2-5cm 358 (44.7) 
        > 5cm 43 (5.4) 
Histology   
        Ductal 638 (79.7) 
        Lobular 118 (14.7) 
        Other 45 (5.6) 
T stage   
        T1 413 (51.6) 
        T2 342 (42.7) 
        T3 38 (4.7) 
        T4 8 (1.0) 
Grade   
        I 91 (11.4) 
        II 502 (62.7) 
        III 208 (26.0) 
Nodal status   
        N0 492 (61.4) 
        N1 226 (28.2) 
        N2 51 (6.4) 
        N3 32 (4.0) 
Menopausal status   
        Pre-Menopausal 167 (20.8) 
        Peri-Menopausal 51 (6.4) 
        Post-Menopausal 583 (72.8) 
Receptor status   
        ER+ 681 (85.0) 
        ER- 120 (15.0) 
        PgR+ 563 (70.3) 
        PgR- 238 (29.7) 
        HER2+ 110 (13.7) 
        HER2- 691 (86.3) 
        HR+ 688 (85.9) 
        HR- 113 (14.1) 
Receptor defined subtype   
        Luminal A-like 510 (63.7) 
        Luminal B-like (HER2 positive) 74 (9.2) 
        Luminal B-like (HER2 negative) 104 (13.0) 
        HER2 positive (non-luminal-like)  36 (4.5) 
        TNBC 77 (9.6) 
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4.1.2 Unsupervised clustering of protein expression profiles in patients 
with breast cancer 
Michaela Bayerlová and I decided to investigate the patient profiles of 37 metabolism-
related proteins by assessing their distribution via unsupervised hierarchical clustering. 
As a result, illustrated by the upper dendrogram coloring in Figure 10, clustering 
divided the whole cohort into two patient clusters (green, n = 440; violet, n = 361). 
 
 
Figure 10 - Unsupervised clustering of protein profiles. 
The heatmap represents expression levels of 37 metabolism related proteins after 
unsupervised hierarchical clustering. The data set consists of 801 tumor specimens. Z-scores 
of log2 transformed protein expression levels are color coded on a low-to-high scale (green –
black- magenta). Dendrogram branches divide the patient set into a green and violet cluster 
and protein targets into a ‘diffuse’ and ‘compact’ cluster. Annotation bars include receptor 
defined subtypes (a); Histological grade (b); Histology (c); Menopausal status (d); Nodal status 
(e) and T stage (f). 
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As presented in Figure 10, the distribution of clinical factors (illustrated as labels a, b, 
c, d, e and f, above the heatmap) showed no significant association with the green and 
violet patient cluster. 
To elucidate a potential association with survival, M. Bayerlová performed Kaplan-
Meier analysis of the two patient clusters (Figure 11). 
 
 
Figure 11 - Kaplan-Meier analysis of green and violet patient cluster. 
Kaplan-Meier curves show proportions of overall survivors (OS) and recurrence-free survivors 
(RFS) of two separate clusters (green and violet). Statistical difference in outcome between 
Kaplan-Meier curves were compared by log-rank test. pval, p value. 
 
As shown in Figure 11, no significant association with OS or RFS was detected. 
However, after observing the heatmap pattern more closely, a distinct horizontal 
partition of the protein targets showed up as a dominant feature of the heatmap. 
Furthermore, a separation into two protein expression clusters indicated a potential 
functional difference throughout the whole patient cohort. Therefore, I divided the 
protein targets by the given dendrogram (depicted on the left-hand side of the heatmap) 
into two protein cluster subgroups, a ‘diffuse’ cluster (blue, n = 19), characterized by 
a heterogeneous protein expression pattern and a ‘compact’ cluster (gold, n = 18) with 
clear protein expression pattern (Figure 10). Notably, the impact of the ‘compact’ 
protein cluster in driving the initial heatmap clustering and formation of the two patient 
clusters, seemed to subdue the effects of the ‘diffuse’ protein cluster. Since no 
differences in survival of the ‘compact’ cluster were observed, I focused on re-
investigating the ‘diffuse’ protein cluster separately. 
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4.1.3 ‘Diffuse’ protein signature revealed three patient clusters 
significantly associated with survival 
Unsupervised hierarchical clustering of the 19 protein targets represented in the 
‘diffuse’ cluster was performed over all patient specimens. Eliminating all proteins of 
the ‘compact’ cluster, resulted in a heterogenous heatmap with three refined patient 
clusters based on the dendrogram arrangement, depicted in blue (n = 242), yellow (n 
= 89) and brown (n = 470), (Figure 12A). 
Based on the resulted dendrogram, the patient clusters were compared for survival 
analysis in terms of OS and RFS outcome. This revealed a significant difference 
among the clusters in both, OS (p = 0.023, Figure 12B) and RFS (p = 0.0071, Figure 
12C), as illustrated in the Kaplan-Meier curves. The blue cluster showed the most 
favorable overall and recurrence-free survival, whereas the yellow cluster represented 
the least favorable outcome. Clinical parameters (age, tumor size, histology, T stage, 
grade, node status, menopausal status and receptor defined status) were further 
examined by M. Bayerlová for differences in distribution between the patient clusters. 
Univariate comparison across the patient’s groups showed that all clinical parameters 
were significantly different between the three clusters (p ≤ 0.05). Furthermore, 
multivariate analysis was conducted based on selected clinicopathological covariates 
(Appendix, Table S1). 
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Figure 12 - Unsupervised clustering and analyses based on ‘diffuse’ cluster 
refinement. 
The heatmap represents metabolism related protein expression levels of the ‘diffuse’ target 
signature after unsupervised hierarchical clustering of 801 tumor specimen. Z-scores of log2 
transformed protein expression levels are color coded on a low-to-high scale (green –black- 
magenta). Annotation bars include receptor defined subtypes (a); Histological grade (b); 
Histology (c); Menopausal status (d); Nodal status (e) and T stage (f). Statistical analysis of 
the three patient clusters (blue, yellow, brown) is shown in the Appendix (Table S1). Kaplan-
Meier curves visualize the proportion of overall survivors (B) and recurrence-free survivors 
(C), compared by log-rank test. pval, p value. 
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4.1.4 The proteomic network of the ‘diffuse’ and ‘compact’ cluster 
In respect to outcome, the different clinicopathological features represented between 
the unique cluster separation of Figure 10 merited a deeper investigation. Therefore, I 
was interested in the differences between the compact and diffuse protein cluster which 
had resulted from the initial clustering and explored their proteomic network. To 
visualize the biological context of the proteins representing the ‘diffuse’ and ‘compact’ 
clusters at a glance, I visualized them in two protein networks by using the STRING 
Database (Figure 13). 
 
 
Figure 13 - Protein network visualization. 
STRING illustrations are based on proteins represented in the ‘compact’ cluster subgroup (A) 
and proteins represented in the ‘diffuse’ cluster subgroup (B). STRING visualization was 
performed for each group individually and the evidence based network edges were set to an 
interaction score of 0.4. The given legend shows the type of interactions that were selected 
for the visualization. 
 
The STRING visualization resulted in distinct interaction nodes, illustrating possible 
protein relations. As part of the ‘diffuse’ cluster, all proteins related to glycine 
synthesis (SHMT2), lipid and fatty acid synthesis (FASN, STARD10, ACACA, 
SREBF1), as well as glycolysis and lactate production (GLUT1, GAPDH, PKM2, 
LDHA, LDHB) were observed. The ‘compact’ cluster in comparison is composed of 
all measured proteins associated with serine synthesis (PHGDH, PSAT1, PSPH). 
Pyruvate kinase isozyme M1 (PKM1) was the only glycolysis related protein 
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represented in the ‘compact’ cluster. Proteins related to the TCA cycle, urea cycle and 
glutaminolysis, were found in both, the ‘diffuse’ and the ‘compact’ cluster. 
In addition, I considered pathway enrichment analysis, however due to the relatively 
low numbers of measured proteins, M. Bayerlová could not detect any enriched 
pathways. Therefore, I decided to shift the main focus of the study towards biomarker 
discovery and further investigate the individual protein target expressions that shaped 
the whole initial clustering. 
 
4.1.5 Correlations between individual target expression and 
clinicopathological characteristics 
In order to identify individual proteins associated with survival and to evaluate their 
potential role as biomarkers, I next analyzed the expression of all probed proteins 
individually. The association of each protein expression level with OS and RFS was 
tested via univariate Cox proportional hazard regression models by M. Bayerlová and 
protein expression was treated as a continuous variable (Full table: Appendix, Table 
S2). Out of 37 metabolism related proteins tested, SHMT2 and ASCT2 were found to 
be significantly associated with overall survival (Table 3). 
 
Table 3 - Protein targets significantly associated with overall survival (OS) 
Target HR 95 % CI P FDR Affiliation 
      
SHMT2 1.93 1.48 – 2.51 <0.001 <0.001 Serine Metabolism 
ASCT2 1.83 1.39 – 2.42 <0.001 <0.001 Glutamine Metabolism 
OS events: 83; p, p value; HR, Hazard Ratio; FDR, false discovery rate; CI, confidence intervals 
 
Furthermore, univariate Cox analysis of recurrence-free survival, revealed 6 out of 37 
proteins to be significantly associated with outcome (Table 4). 
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Table 4 - Protein targets significantly associated with recurrence-free survival 
(RFS) 
Target HR 95 % CI P FDR Affiliation 
      
SHMT2 1.88 1.50 – 2.36 <0.001 <0.001 Serine Metabolism 
ASCT2 1.83 1.45 – 2.31 <0.001 <0.001 Glutamine Metabolism 
GAPDH 1.52 1.19 – 1.94 <0.001 0.009 Glucose Metabolism 
FH 1.65 1.20 – 2.27 0.002 0.019 TCA Cycle 
CAD 2.07 1.29 – 3.33 0.003 0.019 Pyrimidine Metabolism 
PKM2 1.46 1.13 – 1.88 0.003 0.020 Glucose Metabolism 
RFS events: 109; p, p value; HR, Hazard Ratio, false discovery rate; CI, confidence intervals 
 
After having revealed which protein expression profiles were univariately associated 
with survival, the breast cancer patients were grouped depending on “low” and “high” 
protein expression concerning these targets, to explore relationships with other 
clinicopathological variables. This was based on the median protein expression of 
SHMT2, ASCT2, GAPDH, FH, CAD and PKM2 (Appendix, Table S3). Univariate 
analysis showed that all six protein expression profiles were significantly associated 
with tumor size, T stage, grade, nodal status and receptor defined subgroups. Except 
for CAD, all proteins showed a significant association with histology, whereas PKM2 
displayed the only protein profile that significantly correlated with age. No significant 
difference between protein expression and menopausal status was observed. 
 
4.1.6 SHMT2 and ASCT2 protein expression as independent prognostic 
factors in patients with breast cancer 
To confirm the findings, multivariate Cox analyses for overall and recurrence-free 
survival was performed based on selected clinicopathological covariates and 
univariate significance. Proteins showing significance in the univariate Cox analysis 
were included (Full table: Appendix, Table S4). 
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Table 5 - Univariate and Multivariate Cox regression analysis of overall 
survival 
 
 
Univariate 
analysis 
SHMT2 ASCT2 
Characteristics 
Multivariate analysis Multivariate analysis 
p Hazard Ratio (95% CI) p Hazard Ratio (95% CI) p 
Protein expression high vs. low 
 
1.53(1.10-2.12) 0.011 1.23(0.90-1.68) 0.194 
Age at surgery (years) <0.001 1.06(1.03-1.09) <0.001 1.06(1.03-1.08) <0.001 
Tumor size <0.001 Not included 
 
Not included 
 
        < 2cm 
     
        ≥ 2-5cm 
     
        > 5cm 
     
Histology 0.306 Not included 
 
Not included 
 
        Ductal vs. non-ductal 
     
T stage <0.001 
    
        T1 vs. ≥T2 
 
1.46(0.88-2.40) 0.141 1.49(0.90-2.47) 0.123 
Grade <0.001 
    
        I 
 
Reference 
 
Reference 
 
        II 
 
1.69(0.52-5.49) 0.385 1.77(0.54-5.76) 0.345 
        III 
 
2.40(0.70-8.23) 0.163 2.95(0.87-9.99) 0.081 
Nodal status <0.001 
    
        N0 vs. ≥N1 
 
1.86(1.18-2.92) 0.007 1.85(1.17-2.92) 0.008 
Menopausal status 0.001 
    
        Pre-/Peri- vs. Post-Menopausal 
 
0.72(0.28-1.85) 0.489 0.80(0.31-2.05) 0.640 
Receptor status 
     
        ER- vs. ER+ <0.001 Not included 
 
Not included 
 
        PgR- vs. PgR+ <0.001 Not included 
 
Not included 
 
        HER2- vs. HER2+ 0.682 Not included 
 
Not included 
 
        HR- vs. HR+ <0.001 0.72(0.42-1.22) 0.217 0.63(0.37-1.06) 0.082 
Receptor defined subtypes <0.001 Not included 
 
Not included 
 
        Luminal A-like 
     
        Luminal B-like (HER2 positive) 
     
        Luminal B-like (HER2 negative) 
     
        HER2 positive (non-luminal-like)  
     
        TNBC 
 
        
CI, confidence interval; A p value < 0.05 is considered statistically significant 
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Table 6 - Univariate and Multivariate Cox regression analysis of recurrence-
free survival 
 
 
Univariate 
analysis 
SHMT2 ASCT2 
Characteristics 
Multivariate analysis Multivariate analysis 
p Hazard Ratio (95% CI) p Hazard Ratio (95% CI) p 
Protein expression high vs. low 
 
1.54(1.16-2.04) 0.003 1.31(1.01-1.71) 0.042 
Age at surgery (years) <0.001 1.04(1.02-1.07) <0.001 1.04(1.02-1.06) <0.001 
Tumor size <0.001 Not included 
 
Not included 
 
        < 2cm 
     
        ≥ 2-5cm 
     
        > 5cm 
     
Histology 0.110 Not included 
 
Not included 
 
        Ductal vs. non-ductal 
     
T stage <0.001 
    
        T1 vs. ≥T2 
 
1.77(1.15-2.74) 0.010 1.80(1.16-2.80) 0.009 
Grade <0.001 
    
        I 
 
Reference 
 
Reference 
 
        II 
 
1.79(0.65-4.98) 0.262 1.85(0.66-5.14) 0.240 
        III 
 
2.18(0.75-6.35) 0.154 2.64(0.92-7.59) 0.072 
Nodal status <0.001 
    
        N0 vs. ≥N1 
 
1.62(1.10-2.40) 0.015 1.59(1.07-2.35) 0.021 
Menopausal status 0.010 
    
        Pre-/Peri- vs. Post-Menopausal 
 
0.65(0.31-1.38) 0.263 0.73(0.35-1.54) 0.410 
Receptor status 
     
        ER- vs. ER+ <0.001 Not included 
 
Not included 
 
        PgR- vs. PgR+ <0.001 Not included 
 
Not included 
 
        HER2- vs. HER2+ 0.489 Not included 
 
Not included 
 
        HR- vs. HR+ <0.001 0.79(0.49-1.27) 0.334 0.69(0.43-1.10) 0.115 
Receptor defined subtypes <0.001 Not included 
 
Not included 
 
        Luminal A-like 
     
        Luminal B-like (HER2 positive) 
     
        Luminal B-like (HER2 negative) 
     
        HER2 positive (non-luminal-like) 
     
        TNBC 
 
        
CI, confidence interval; A p value < 0.05 is considered statistically significant 
 
The analyses of the association between SHMT2/ASCT2 protein expression levels and 
clinical characteristics of BC via multivariate Cox models was conducted to address 
the question whether SHMT2 and ASCT2 protein expression are independent 
prognosticators for OS and RFS. This revealed, that high SHMT2 protein expression 
is indeed an independent negative prognostic factor for OS (p = 0.011; Table 5) and 
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both, high SHMT2 and high ASCT2 protein expression levels are independent 
negative prognostic factors for RFS (SHMT2, p = 0.003; ASCT2, p = 0.042; Table 6) 
in BC patients. Kaplan–Meier survival estimates, based on dichotomized protein 
expression data, subsequently confirmed that BC patients with high SHMT2, as well 
as high ASCT2 protein expression presented a significantly unfavorable OS time 
(SHMT2, p = <0.001; ASCT2, p = 0.0165) and RFS time (SHMT2, p = <0.001; 
ASCT2, p = <0.001), (Figure 14). 
 
 
Figure 14 - Kaplan-Meier survival estimates and boxplot representation of key 
targets associated with survival. 
Kaplan-Meier plots of SHMT2 and ASCT2 for overall survival (OS), (A), and recurrence-free 
survival (RFS), (B). Statistical difference in outcome between high (n = 400) and low (n = 401) 
protein expression were compared by log-rank test. Boxplots represent the relative target 
protein expression per receptor defined subtype, Luminal A-like (n = 510), Luminal B-like 
HER2neg (n = 104), Luminal B-like HER2pos (n = 74), HER2pos (n = 36), TNBC (n = 77). 
FDR, false discovery rate; pval, p value. 
 
Additionally, I explored the distribution of SHMT2 and ASCT2 protein expression 
across BC subtypes. This revealed a higher protein expression of both targets in the 
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aggressive HER2 positive and the triple negative (TNBC) breast cancer subtype, as 
compared to the luminal subgroups (Figure 14). 
In collaboration with PD Dr. med. Jörg Buchmann of the Institute of Pathology, 
Hospital Martha-Maria (Halle(Saale), DE), the results from my screen were confirmed 
in clinical practice via SHMT2 and ASCT2 immunostaining of representative cases. 
As illustrated in Figure 15, the cases selected on the basis of the RPPA data are in line 
with the observed cellular target expression pattern of SHMT2 and ASCT2. Cases of 
high target protein expression in RPPA also represented a high cellular target protein 
expression in IHC and vice versa. 
 
 
Figure 15 - Representative immunoexpression of SHMT2 and ASCT2. 
Cases were selected on basis of RPPA protein expression results. The figure shows 
representative pictures of the highest or lowest 10% cases based on the target expression 
over all cases. SHMT2 immunoexpression is elevated in Case M571 and low in Case M1084. 
ASCT2 immunoexpression is elevated in Case M1199 and low in Case M907. The scale bar 
indicates 200 μm (20x). 
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Taken together, these results illustrate the prognostic value of profiling proteome data 
and highlight the importance of the proteomic level in biomarker research. All 
presented results are further discussed in Chapter 5. 
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4.2 Proteomic profiling of metabolic adaptations in hypoxic 
conditions 
 
4.2.1 Experimental rationale and generation of linear regression model 
In order to approach the proteomic profiling of metabolic changes under dynamic 
hypoxic conditions, I used 4 different breast cancer cell lines (MCF-7, SKBR3, MDA-
MB-231 and MDA-MB-468) for my perturbation experiments. All cell lines were 
treated individually under the same conditions. The cell lines were incubated in 
normoxic (21% O2), mild hypoxic (1.2% O2), strong hypoxic (0.2% O2) and MIMIC 
conditions (200µM CoCl2) in a time dependent manner. The protein was harvested 
after 0h, 6h, 18h and 24h of incubation and after a 2h re-oxygenation at 26h. To obtain 
quantitative expression data, the protein lysates were further processed via RPPA and 
protein array slides were probed with antibodies targeting 40 metabolism related 
proteins. Thereby, the selected set of protein targets reflects the full spectrum of 
metabolism related proteomic targets used in the breast cancer patient’s cohort and 
three additional proteins of interest. The full list of antibodies used during my projects 
is illustrated in Chapter 3, Section 3.1.5. After performing the raw data analysis and 
quality control, I reached out to investigate the data in more depth and collaborated 
with Christian Tönsing of the Institute of Physics at the University of Freiburg (DE). 
Together, we decided to create a linear regression model (LRM) of the data matrix in 
order to statistically define which target expression is altered under the given 
conditions. 
 
 
Figure 16 - Experimental workflow. 
Schematic presentation of the experimental workflow and analysis. 
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The preprocessed RPPA time course data with biological triplicates for each time point 
were analyzed by C. Tönsing individually for each of the target proteins and for each 
of the 12 combinations of cell lines and treatments. A linear regression model was used 
for the log2 signal intensities of the target protein time courses and cell line-treatment 
combination individually, to merge the replicates and asses the kind and strength of 
regulation. ANOVA was applied to each time course in order to discriminate between 
a constant time course signal at the basal expression level of the target protein and 
significantly regulated expression profiles (p < 0.05). The linear regression model 
further served to illustrate the data and for approaches to determine top-regulated 
targets. The experimental workflow is depicted in Figure 16. 
 
4.2.2 Heatmap representation of the dataset via a linear regression 
model 
In a first step, the linear regression model was used to visualize the whole data set. 
Therefore, target protein regulation profiles were assigned based on time point specific 
regulation strengths from the LRM. Only significantly regulated estimates with 
p[t{6,18,24}] < 0.05 compared to the basal expression level were used to identify 
either a up or down regulation. Time courses with one, two or three significantly up-
regulated time points were assigned to expression profiles ‘one up’, ‘two up’ and ‘all 
up’, respectively and likewise for down-regulated signals. Time courses with 
alternating sign, i.e. a significant down-regulation followed by a not significant 
regulation and further by a significant up-regulation were specified as ‘down-up’, 
while the opposite was termed as ‘up-down’. A double sign-change of significantly 
regulations, e.g. ‘up-down-up’ was not observed in the dataset. All other time courses 
with no significant regulation were assigned to ‘constant’ profiles. The resulting 
heatmap represents all target protein regulation profiles per cell line and condition 
(Figure 17). The corresponding color coding is displayed and explained in the 
corresponding legend. 
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Figure 17 - Heatmap visualization of protein time course profiles. 
The heatmap represents the condensed time course data of each target on the basis of the 
linear regression model results. Protein target expression direction, during treatment exposure 
is color coded and clarified in the figure legend on the right-hand side. 
 
As a result, the heatmap showed a quite diverse pattern. Nevertheless, the behavior of 
HIF-1α, displayed as upregulated in all hypoxic and mimic conditions and over all cell 
lines, confirmed the power of the LRM and its visualization. No obvious pattern of a 
whole metabolic pathway matching with a treatment condition could be observed. 
However, individual target regulation profiles (e.g. GLUT1) seemed to be heavily 
influenced in all hypoxic conditions and cell lines. Therefore, I decided to statistically 
approach the data set in order to elucidate individual top-regulated targets. 
 
4.2.3 Identification of top-regulated target proteins 
Given the complex picture of the heatmap visualization, two different statistical 
approaches were utilized to investigate the top-regulated target proteins. First, I 
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analyzed top-regulated targets via a ‘Cell line (Cl) score’ (Figure 18A). The Cl Score 
enables the identification of top-regulated target proteins in all cell lines and treatment 
combinations. For each treatment, the Cl Score indicates the number of target proteins, 
with expression time courses indicating for a significant regulation throughout all cell 
lines. A pANOVA of < 0.05 has to be fulfilled by a target protein expression time 
course of a cell line/treatment combination to be identified as significantly regulated. 
A Cl Score of 0 indicates the number of target time courses which are not significantly 
regulated in any cell line, whereas a Cl Score of 1 indicates the number of target time 
courses significantly regulated in 1 cell line, a Cl Score of 2 in 2 cell lines, a Cl Score 
of 3 in 3 cell lines and a Cl Score of 4 in all four cell lines. The full data matrix of 
Figure 18A can be found in the Appendix (Table S6). 
Next, C. Tönsing used a different second indicator for top-regulated target proteins, a 
regulation ranking combined by the rank product [139]. For this, target proteins were 
ranked by two measures to obtain the strength of the regulation for each combination 
of cell line and treatment individually. The first measure is the summed square of 
residuals (SSR) from the ANOVA, if pANOVA < 0.05 which is sensitive for sustained 
expression profiles. The second measure ranks the target proteins by the absolute value 
of the maximal time point specific regulation in the time course and thus takes account 
of peaked expression profiles. The two rankings are combined by the rank product for 
each cell line and treatment combination. The ‘rank by treatment’ contains rank 
product combinations in all cell lines, for each treatment individually. In a last step, 
treatment ranks were combined by the rank product yielding the ‘overall rank’. A low 
rank number thereby indicates a high ranked target, whereas a high rank number 
indicates a low ranked target (Figure 18B). 
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Figure 18 - Determination of top-regulated protein targets. 
Illustrated are the results from the Cell line (Cl) Score analysis (A) and the rank product 
analysis (B). Furthermore, the reaction of one of the top-targets GLUL is shown in (C). 
 
As presented in Figure 18A, the highest Cl Score was presented by 4 target time 
courses in the mild hypoxic condition (1.2% O2), 7 target time courses in the strong 
hypoxic condition (0.2% O2) and 7 targets in the MIMIC condition (200µM CoCl2). 
As highlighted in blue, it was striking that out of all targets, three target time courses 
(HIF1_alpha, GLUT1 and GLUL) were found to be significantly regulated in all 
treatment conditions and all four cell lines. This observation was further validated by 
the second approach, the rank product, were HIF1_alpha, GLUT1 and GLUL achieved 
the highest ‘Overall ranks’ together with LDHA. 
In order to provide an in-depth view on the top-targets during hypoxia exposure, the 
time course data of each target were extracted and depicted in Figure 19. 
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Figure 19 - LRM and time course data of top-regulated protein targets. 
Illustrated are the time course data of HIF1_alpha, GLUL, LDHA and GLUT1 per condition and 
cell line. Indicators for protein signals and LRM parameters are described in the legend. 
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As shown in Figure 19, the protein expression of the hypoxia-inducible factor 1 alpha 
is elevated under hypoxic conditions in all cell lines and conditions. This observation 
confirms the experimental design and analysis. Further, the protein expression profiles 
of GLUT1 and LDHA were found to be mostly elevated under hypoxic conditions, 
whereas GLUL protein expression levels were mostly down regulated. Since HIF-1α 
served as internal control and GLUT1 and LDHA are known to be effected by hypoxic 
conditions, which I will further discuss in Chapter 5, I decided to follow up on the 
novel connection of hypoxia and GLUL in breast cancer. The glutamate-ammonia 
ligase (GLUL) pathway is illustrated in Figure 18C. 
 
4.2.4 GLUL expression profile 
After elucidating GLUL as one of the top-regulated targets during hypoxia exposure, 
I next wanted to know how the expression profile of GLUL is represented in breast 
cancer patients. Therefore, I used The Cancer Genome Atlas (TCGA) data which was 
conducted on primary breast cancer tumor specimen with both RNA-sequencing data 
and clinical annotations. Normalized gene expression data from the cBioPortal website 
was obtained, log2 transformed and filtered for the genes of interest. Further, a one-
way analysis of variance (ANOVA), was conducted to differentiate between breast 
cancer subtypes. The gene expression profile of GLUL in different breast cancer 
subtypes is shown in Figure 20. 
 
Figure 20 - GLUL expression profile. 
Boxplots represent the log2 GLUL gene expression in comparison to other glutamine related 
targets (A) and across different breast cancer subtypes (B). p, p value.  
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Interestingly, GLUL mRNA expression was found to be the highest among all 
glutaminolysis related genes in the TCGA dataset (Figure 20A). Furthermore, GLUL 
gene expression was significantly different between the BC subtypes and higher in the 
luminal breast cancer subtype in comparison to the basal subtype (Figure 20B). 
As reported in Chapter 1, hypoxic conditions and the basal breast cancer subtype are 
associated with a poorer prognosis in comparison to well oxygenized tumors and the 
luminal subtype. 
 
4.2.5 GLUL survival association 
After observing decreased protein expression of GLUL under hypoxic conditions and 
lower gene expression in the basal subtype, I was interested to investigate the impact 
of GLUL expression on overall survival (OS) and recurrence-free survival (RFS). 
I performed Kaplan-Meier survival analysis in terms of OS and RFS outcome. This 
revealed a significant difference between high and low GLUL gene expression in both, 
OS (p = 0.0027, Figure 21A) and RFS (p = 0.0173, Figure 21B), as illustrated in the 
Kaplan-Meier curves. High GLUL expression showed the most favorable OS and RFS, 
whereas low GLUL expression represented the worst. 
Furthermore, the correlation of GLUL gene expression with the Tumor (T) stage was 
analyzed. As shown in Figure 21C, lower GLUL expression is significantly correlated 
with a higher T stage and vice versa. Moreover, GLUL mRNA expression in high and 
low HIF-1α expressing subgroups of breast cancer cases were analyzed. As shown in 
Figure 21D, GLUL expression is significantly elevated in the HIF-1α low patient 
subgroup whereas low GLUL expression is associated with the HIF-1α high 
expressing patient subgroup. 
In conclusion, after I generated dynamic time course data of 40 metabolic proteins 
under hypoxic and MIMIC conditions, C. Tönsing and I were able to provide an 
overview of significant changes in protein regulation profiles under the given 
conditions and further elucidated top-regulated targets. With a focus on the novel 
associations of the hypoxic driven GLUL expression changes, I elaborated on clinical 
correlations with GLUL. All results are further discussed in Chapter 5. 
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Figure 21 - Kaplan-Meier survival estimates of GLUL gene expression and 
boxplot representation of T stage and HIF1-alpha association. 
Kaplan-Meier plots of GLUL for overall survival (OS), (A), and recurrence-free survival (RFS), 
(B). Statistical difference in outcome between high and low gene expression were compared 
by log-rank test. Boxplots represent the target gene expression in association to T stage (C) 
and HIF1-alpha expression subgroups (D). p, p value. 
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Since breast tumors are heterogenous at the molecular level and in patient outcome, 
clinical management includes an individual tumor characterization, which leads to 
personalized treatment decisions. However, this is mostly based on the measurement 
of few parameters, i.e. gene/protein expression status of ER, PR, and HER2. So far, 
the metabolic state of tumors has not been widely studied and is insufficiently covered 
with current molecular biomarkers that are predictive for clinical outcome. Even 
though RNA does inform on phenotypic characteristics, genomic and transcriptomic 
screens of BC patient tumors have thus far proven unsuccessful to predict protein states 
[140], [141]. Therefore, complementary studies investigating the metabolic landscape 
of breast cancer at the proteomic level should be superior in identifying metabolism 
based biomarkers with clinical impact. 
 
5.1 Proteomic profiling of breast cancer metabolism identifies 
SHMT2 and ASCT2 as prognostic factors 
 
In the first part of my PhD project, I wanted to assess the relationship between protein 
profiles of major metabolic targets/pathways and their potential prognostic value in 
breast cancer patients. 
As a first result, cluster analysis of the generated dataset separated the metabolism 
associated proteins into a ‘diffuse’ and a ‘compact’ protein cluster, indicating different 
metabolic profiles. STRING visualization results of the protein distribution depicted a 
prominent role of glycolysis and lactate production in the ‘diffuse’ cluster. Also, 
SHMT2, primarily responsible for glycine synthesis from serine, was part of the 
‘diffuse’ cluster, whereas all proteins of the serine pathway (PHGDH, PSAT1, PSPH) 
were part of the ‘compact’ cluster. Interestingly, key enzymes of the TCA cycle, 
crucial for citrate production like FH and SDHA, were present in the ‘diffuse’ cluster, 
whereas IDH1 and IDH2, which mainly drive the TCA cycle towards α-ketoglutarate 
production were part of the ‘compact’ cluster. This observation was supported by the 
presence of PDH, STARD10 as well as FASN in the diffuse cluster and hints towards 
a distinct citrate production in order to fuel the lipid and fatty acid synthesis. Mullen 
et al. reported in 2011 this metabolic flexibility in cancer cells. Normally, cells 
Chapter 5 
80 
condense glutamine-derived oxaloacetate with glucose-derived acetyl-CoA to produce 
citrate, whereas cells with defective mitochondria reverse part of their citric acid cycle 
using NADPH dependent isocitrate dehydrogenases (IDHs) to convert a-ketoglutarate 
to isocitrate via reductive carboxylation. Therefore, glutamine can reverse citric acid 
cycle reactions, such that reductive carboxylation yields acetyl-CoA for lipid 
synthesis. Despite the association between defective mitochondria and oncogenesis, 
the authors highlight the central importance of mitochondria in cancer, even when 
theses do not generate ATP [142]. 
Notably, the glutamine transporters ASCT2 (SLC1A5) and SLC7A5, as well as the 
glutamine producing enzyme GLUL, were also part of the ‘diffuse’ cluster. Altogether, 
the protein composition of the ‘diffuse’ cluster points towards glucose consumption, 
glutamine addiction and glycine production and indicates a more active Warburg like 
characteristic in comparison to the ‘compact’ cluster [51]. 
Following up on the ‘diffuse’ protein cluster, subsequent clustering analysis identified 
three patient clusters, which are significantly associated with survival. These three 
patient clusters do not fully reflect the receptor defined subtypes of BC and may thus 
provide a different angle towards understanding breast cancer heterogeneity. 
Interestingly, further analysis showed, that all proteins that were found to be 
significantly correlated with survival were part of the ‘diffuse’ cluster. SHMT2, 
ASCT2, GAPDH, FH, CAD and PKM2 were univariately associated with RSF and 
SHMT2, as well as ASCT2 with OS. Consequently, an exploration of the biomarker 
potential of these proteins in multivariate cox analyses was conducted. 
Multivariate analysis identified SHMT2 and ASCT2 protein expression levels to be 
significantly associated with age, nodal status, and T Stage (RFS only). Moreover, 
high SHMT2 protein levels were significantly associated with poor RFS and OS. 
Furthermore, high protein expression of ASCT2 was significantly correlated with poor 
RFS. Patients of HER2 positive and HR-negative breast cancer demonstrated 
increased SHMT2 and ASCT2 levels compared to luminal-like patients. Notably, the 
significant correlation of ASCT2 and SHMT2 with nodal status, T stage as well as 
survival, indicates a connection between higher metabolic activity and associated 
protein expression in metastatic and further progressed tumors. These observations are 
in line with previous studies reporting that metabolic demands of cancer cells are 
related to their cell size, progression and protein synthesis rates [143]. 
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Glutamine metabolism is considered to be a therapeutic target, as some cancer cells 
exhibit high uptake of this non-essential amino acid [51]. Recent studies have 
demonstrated that the primary glutamine transporter, ASCT2, promotes tumor cell 
survival, growth and cell cycle progression in neuroblastoma, colorectal cancer, 
prostate cancer, clear-cell renal cell carcinoma and non-small cell lung cancer [144], 
[145], [146], [147], [148]. Consequently, ASCT2 has gained more attention during the 
last years as its ubiquitous tissue expression, along with its ability to transport crucial 
amino acids, indicates a central role in physiological processes including glutamine 
homeostasis, embryogenesis, retroviral infection and cancer development [149], [150], 
[151]. Glutamine is not only an important nutrient for cancer cell survival, but also a 
crucial mediator for immune cell functions. ASCT2 was shown to be involved in 
inflammatory T cell responses, which might exert key functions in tumor immunity 
[152]. ASCT2 regulates the cellular uptake and concentration of nutrients and several 
studies indicate that blocking glutamine uptake might be an attractive strategy for 
cancer therapy [153], [154]. The presented results showed that high protein levels of 
ASCT2 are correlated with unfavourable prognosis for breast cancer patients. Along 
these lines, blocking the glutamine uptake by utilizing ASCT2 as a potential 
therapeutic target and reducing its protein expression, could be a promising approach. 
In addition to glutamine, the serine and glycine metabolism is also crucial in cancer 
cell development. Serine and glycine are biosynthetically linked and, besides cancer 
growth, also affect the cellular antioxidative capacity, thus supporting tumor 
homeostasis. SHMT2 has been implicated as an essential factor in serine and glycine 
metabolism in several cancer cell types, including breast cancer [62]. SHMT2 
catalyzes the reversible reaction of serine and tetrahydrofolate to glycine and 5,10-
methylene tetrahydrofolate. Studies have shown that high levels of glycine are 
associated with poor prognosis in breast cancer, irrespective of the ER status [155]. I 
demonstrated that high protein levels of SHMT2 are correlated with poor outcome in 
breast cancer patients. Inhibition of glycine synthesis by reducing SHMT2 protein 
expression, could therefore, represent a new treatment strategy to employ SHMT2 as 
a potential therapeutic target. Notably, to date there are no SHMT2 and ASCT2 
inhibitors available for cancer therapy and to my best knowledge these are the first 
observations to report the prognostic value of SHMT2 and ASCT2 at the protein 
expression level in breast cancer patients.  
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5.2 Hypoxic regulation of metabolism associated enzymes in 
breast cancer 
 
The criteria to be used in evaluating tumor metabolism are still not well established 
and universally applied. Furthermore, it is mostly unclear how metabolic 
characteristics are influenced by tumor microenvironmental factors like hypoxia and 
how this might influence tumor development. Therefore, it is necessary to obtain a 
better understanding of molecular mechanisms underlying the heterogeneity of breast 
cancer metabolism in different microenvironmental milieus. 
In the second part of my PhD project, I thus investigated the time dependent expression 
changes of metabolism related proteins under different hypoxic conditions. Therefore, 
I generated proteomic time course data using RPPA.  
In a first approach, the data was visualized using a unique heatmap method that showed 
an upregulation of HIF-1α in all hypoxic and mimic conditions and over all cell lines, 
confirming the experimental procedure and the LRM. Interestingly, the heatmap 
pattern revealed a very diverse picture of all protein expression time courses tested. I 
did not observe an obvious connection of any metabolic pathway matching a certain 
treatment condition. Rather, the response patterns hint towards cell line diversity as 
the most prominent feature, reflecting the heterogenous nature of metabolic activities. 
Different tumor cells seem to preferentially utilize particular catabolites. Experimental 
models in ovarian, prostate and breast carcinomas have also revealed a metabolic 
coupling of stromal and cancer cells leading to diverse metabolic profiles [156], [157]. 
Genomic and metabolic differences throughout all cell types might, therefore, also 
result in a different adaption to oxygen deprivation. These observations cloud be the 
reasoning for the diverse behavior across all cell lines. However, a minority of 
individual target regulation profiles seemed to be changed in all conditions and cell 
lines. Consequently, I next elucidated individual top-regulated targets. Two different 
approaches were used in order to confirm the results. Since, similar to the heatmap 
approach, no standard procedure was available to assess the data sufficiently, a Cell 
line (Cl) Score was generated. Scoring the target time courses identified HIF-1α, 
GLUT1 and GLUL as significantly regulated in all cell lines and treatment conditions. 
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Furthermore, besides a high rank of LDHA, also HIF-1α, GLUT1 and GLUL showed 
the highest overall ranks in the rank product approach. These observations not only 
highlight the importance of the given targets as significantly affected under hypoxic 
conditions, it further confirms the results and the robustness of the methods used. 
Further investigation explored all time courses of the top regulated targets individually 
and found the protein expression of HIF-1α to be elevated under all hypoxic conditions 
and in all cell lines. Additionally, the protein expression profiles of GLUT1 and LDHA 
were found to be mostly elevated under hypoxic conditions, whereas GLUL protein 
expression levels were mostly down regulated. 
HIF-1α stabilization in response to environmental factors like hypoxia contributes in 
many ways to a pro-growth glycolytic metabolic program, by synchronizing 
proliferation rates with O2 availability [158]. On the one hand, HIF-1α seems to be a 
perfect drug target for hypoxic tumors, but on the other hand, despite the promise of 
HIF-1 inhibitors as anticancer agents, preclinical and clinical development of many 
agents have been halted because of safety or toxicity concerns [71]. HIF-1α is known 
to be an important contributor to the Warburg effect by inducing the expression of 
genes encoding glycolytic enzymes and glucose transporters [159], [160]. Therefore, 
my results are in line with previous observations, as I could show that the glucose 
transporter GLUT1 is upregulated during HIF-1α stabilization. Furthermore, HIF-1α 
also directly regulates the expression of the enzyme lactate dehydrogenase A (LDHA) 
and the monocarboxylate transporter 4 (MCT4) cell surface transporter, which 
mediates the efflux of lactate from the cell [161]. Promotion of lactate production by 
HIF-1α is a phenomenon, that is also reflected in my data set [162]. GLUT1 and LDHA 
are among the top-regulated targets suggesting that HIF-1α-induced upregulation of 
GLUT1 and LDHA contribute to the effective glycolytic production of lactic acid, a 
feature that has been suggested to promote survival in hypoxic settings [163]. 
Conversion of pyruvate to lactate and its removal by lactate transporters allows cancer 
cells to regenerate NAD+ and maintain glycolytic flux in hypoxia [164]. These findings 
are consistent with prior studies reporting a substantial shift towards anaerobic 
glycolysis as the major metabolic feature of HIF-1α expressing cells. This indicates 
that glycolysis may be the preferred pathway used for energy production in hypoxic 
states. However, under conditions of unlimited nutrient resources, cells are also able 
to utilize a variety of metabolic processes, including OXPHOS to generate energy. 
Drugs that target glycolytic enzymes and transporters of glycolytic products, such as 
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GLUT1 and LDHA have been investigated in several preclinical studies and some, 
like the GLUT1 inhibitor Silibinin are been tested clinically [165], [166], [167]. 
However, no inhibitors of glycolysis have yet been approved as anticancer agents. 
As described above, GLUT1 and LDHA, two of the three top regulated metabolism 
related proteins that I identified in my perturbation experiments, have been broadly 
explored in several studies and thus serve as a benchmark for my results. However, 
these lack novelty for further exploration. Therefore, I focused on exploring the rather 
unknown connection of GLUL and hypoxia. 
Glutamate-ammonia ligase (GLUL), an enzyme which catalyzes the de novo synthesis 
of glutamine from glutamate and ammonia, was found to be significantly perturbed 
during hypoxia exposure in all cell lines. Glutamine, in principle a non-essential amino 
acid, belongs to a group of amino acids that are conditionally essential, particularly 
under catabolic stressed conditions in which glutamine consumption rises dramatically 
[168]. Glutamine is transported into cells through transporters, such as the ASCT2 
transporter, that I found to be significantly associated with survival in breast cancer 
patients and further discussed in depth in the previous section of this Chapter [169]. 
Glutamine can be used for biosynthesis or be exported back out of the cell by 
antiporters in exchange for other amino acids such as leucine [54]. Overall, studies 
with tracer experiments have determined that at least 50% of non-essential amino acids 
used in protein synthesis by cancer cells in vitro, can be directly derived from 
glutamine [170]. Although the crucial role of glutamine metabolism in cancer cell lines 
is well established, it is less clear what role glutamine plays in tumors, where cells can 
face shortages of nutrients and oxygen [171]. I found the glutamine producing enzyme 
GLUL to be down regulated after exposure to hypoxia, indicating a reduced need for 
glutamine under hypoxic conditions. Further, I explored the connections between 
GLUL expression and clinicopathological characteristics of patients, using The Cancer 
Genome Atlas (TCGA) dataset. GLUL mRNA expression was found to be highest 
among all glutaminolysis related genes in the TCGA dataset and significantly higher 
expressed in the luminal breast cancer subtypes in comparison to the basal subtype. 
Furthermore, Kaplan-Meier analysis revealed a significant association of GLUL gene 
expression with both, OS and RFS. The most favorable overall and recurrence-free 
survival was represented by high GLUL expression, whereas low GLUL expression 
correlated with poor outcome. A significant association of lower GLUL expression 
with a higher T stage and vice versa was in line with these observations. 
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GLUL promotes glutamine production which can be used for anabolic processes such 
as synthesis of nucleotides and proteins. These building blocks are crucial for 
proliferation and the growth of cancer cells. My data reflects the general notion for the 
need of high glutamine levels in order to sustain cellular processes, as GLUL was 
found highly expressed in breast cancer patients and the association of high GLUL 
expression and favorable patient survival underlines this aspect. 
In summary, combining all results, poor outcome was found for patients with high 
HIF-1α and low GLUL gene expression. GLUL mRNA expression levels were 
significantly elevated in the HIF-1α low patient subgroup, whereas low GLUL 
expression was associated with the HIF-1α high expressing patient subgroup. These 
results illustrate the association of survival and decreased GLUL expression under 
hypoxic conditions indicating a cellular metabolic switch from proliferation to 
“survival mode” and an inhibition of glutaminolysis during hypoxia. Cells undergo 
cell cycle arrest under conditions of severe hypoxia, but are capable of recovering if 
hypoxia is not prolonged [172]. Therefore, for future studies it would be highly 
interesting to explore GLUL and its association with hypoxic conditions in more depth 
and a possible role of GLUL as hypoxia marker in breast cancer patients. 
Taken together, the maintenance of O2 homeostasis is essential for the survival of most 
species. O2 deprivation triggers complex adaptive responses at cellular, tissue and 
organismal levels to meet the metabolic and bioenergetic demands [173]. Most 
research concerning HIFs and their interaction with the metabolome has mostly 
focused on glycolysis. Revealing the effects of hypoxia using a broad panel of 
metabolism associated proteins has showed metabolic pathways beyond glycolysis 
that are important in cancer adaptation processes.  
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5.3 Concluding remarks and future directions 
 
Cancer was recognized as a disease of altered metabolism nearly 100 years ago, but 
metabolic reprogramming has only recently been recognized as an essential hallmark 
of neoplasia. Mutations in metabolic enzymes can drive tumorigenesis, more often 
however cancer metabolism is transformed by altered abundance and activity of the 
metabolic enzymes [174]. While many of the underlying causes of human disease 
occur at genetic and epigenetic levels, drug response and disease pathophysiology are 
driven by cellular phenotypes that in turn are regulated at the translational protein 
level. 
During the recent years, reverse phase protein arrays (RPPA) have emerged as a 
powerful high-throughput approach for targeted proteomics [109], [121]. RPPA allows 
the quantification of protein expression profiles in large sample sets while requiring 
very low amounts of biological sample. Therefore, the RPPA platform was ideally 
suited for my analysis of clinical materials and biomarker discovery purposes [175], 
[176], [177]. 
With respect to the current focus on outcome-based therapy and precision medicine, 
the identification of novel therapeutic proteins and prognostic biomarkers is critical 
for future clinical patient stratification and drug discovery. 
In the present study, I applied RPPA-based functional proteomics to a large number of 
patient samples from a multicenter prospective cohort, to evaluate the relationship 
between metabolism-associated protein expression profiles and clinicopathological 
characteristics. Clustering results, as well as individual protein expression patterns 
were associated with clinical data. The results showed metabolism associated proteins 
linked to breast cancer progression and metabolic clusters of breast cancer, 
characterized by differences at the proteomic level. Particularly, proteins mapping to 
the ‘diffuse’ cluster, were found to be associated with poor prognosis. Moreover, the 
results highlight the importance of SHMT2 and ASCT2 protein expression as 
independent prognostic factors and potential prognostic biomarkers for breast cancer 
patients, as their high protein expression is associated with poor outcome. 
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The results confirm the reported heterogeneity of breast tumors at a functional 
proteomic level and dissect the relationship between metabolism related proteins, 
pathological features and patient survival. 
Although my project revealed the clinical significance of SHMT2 and ASCT2 in breast 
cancer, some limitations warrant further investigation. For instance, the functional 
roles of SHMT2 and ASCT2. Furthermore, an investigation of an independent cohort 
is needed to validate the findings. Since a long-term follow-up of the patient cohort is 
conducted, continuous monitoring of the prognostic power of the achieved results 
would be a suitable consideration. 
In the second part of my study, I demonstrated that breast cancer cell lines regulate 
their metabolic protein levels in heterogeneous ways during oxygen deprived 
conditions. My results showed a significant regulation of a minor amount of proteins 
in all cell lines and conditions tested, rather than a complete pathway response. Among 
the top-regulated protein targets were known effectors of HIF-1α, such as GLUT1 and 
LDHA. Also, the novel discovery of a significant regulation of GLUL in all cell lines 
and perturbation experiments was observed. Particularly, GLUL showed an inverse 
correlation of protein expression compared to HIF-1α and was further found to be 
associated with survival in breast cancer patients. 
Although first insights into the hypoxic response of metabolism related targets was 
revealed, further investigations are needed to validate the findings. A more 
comprehensive investigation of GLUL and its regulation e.g. in glutamine-deprived 
conditions might foster new insights. The behavior of GLUL overexpressing cells to 
hypoxic conditions could lead to a better understanding of the role of glutaminolysis 
in an oxygen deprived microenvironment. 
In general, revealing new markers of HIF metabolism could lead to a better 
understanding of the phenotype and may enable more successful diagnosis and 
prognosis of patients with hypoxic tumors. Screening tumor extracts for relevant 
hypoxic signatures could thus be a first step towards identifying appropriate 
stratification regimes. Therefore, exploring GLUL and its association with hypoxic 
conditions in future studies and to investigate a possible role of GLUL as a hypoxia 
marker in breast cancer patients, could be a promising approach. 
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Table S1 Relationship between clusters and clinical and pathological characteristics. 
Please refer to the supplemented CD-ROM due to length of the table. 
 
Table S2 Univariate Cox proportional hazard regression models of OS and RFS. 
Target HR lower 95% CI upper 95% CI P FDR 
SHMT2 1.927 1.480 2.51 1.097E-06 4.060E-05 
ASCT2 1.833 1.390 2.42 1.749E-05 0.000 
GAPDH 1.480 1.119 1.96 0.006 0.075 
SDHA 1.860 1.116 3.10 0.017 0.113 
PKM2 1.414 1.056 1.89 0.020 0.113 
FH 1.543 1.068 2.23 0.021 0.113 
GLS 0.649 0.449 0.94 0.021 0.113 
ASS1 1.342 1.022 1.76 0.035 0.160 
ACC 0.618 0.377 1.01 0.057 0.197 
CAD 1.689 0.977 2.92 0.060 0.197 
GOT1 1.456 0.983 2.16 0.061 0.197 
ARG2 1.519 0.968 2.38 0.069 0.197 
GLUT1 1.213 0.985 1.49 0.069 0.197 
LDHA 1.286 0.969 1.71 0.081 0.214 
PCK2 0.810 0.636 1.03 0.087 0.214 
PDH 1.567 0.918 2.67 0.100 0.231 
PCK1 0.645 0.374 1.11 0.115 0.251 
GLK 1.468 0.880 2.45 0.141 0.290 
PSPH 0.795 0.560 1.13 0.199 0.384 
IDH1 1.295 0.866 1.94 0.208 0.384 
LAT1 1.194 0.867 1.65 0.278 0.489 
LDHB 1.224 0.778 1.93 0.382 0.643 
STARD10 0.867 0.609 1.24 0.432 0.653 
ODC1 0.807 0.462 1.41 0.450 0.653 
PKM1 0.850 0.553 1.31 0.459 0.653 
SREBP1 1.132 0.815 1.57 0.459 0.653 
PSAT1 1.154 0.729 1.83 0.541 0.741 
NAGS 0.924 0.672 1.27 0.625 0.820 
FASN 0.961 0.812 1.14 0.643 0.820 
CPS1 1.059 0.809 1.39 0.676 0.834 
GPT2 1.077 0.696 1.67 0.739 0.882 
ASL 0.939 0.610 1.44 0.773 0.894 
IDH2 0.960 0.692 1.33 0.810 0.908 
SMS 0.968 0.651 1.44 0.873 0.950 
PHGDH 1.026 0.658 1.60 0.909 0.961 
Glud12 1.016 0.689 1.50 0.935 0.961 
GLUL 0.995 0.789 1.26 0.968 0.968 
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Table S3 Correlations between key targets expression and patients and tumor 
characteristics. 
Please refer to the supplemented CD-ROM due to length of the table. 
 
Table S4 Univariate and multivariate Cox regression analyses of OS and RFS. 
Please refer to the supplemented CD-ROM due to length of the table. 
 
Table S5 RPPA data expression matrix with matched clinical data. 
Please refer to the supplemented CD-ROM due to length of the table. 
 
Table S6 Cl Score data matrix. 
Please refer to the supplemented CD-ROM due to length of the table. 
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List of Abbreviations 
 
ACC Acetyl-CoA Carboxylase Alpha 
AKT Protein kinase B 
ANOVA Analysis of variance 
ARG2 Arginase 2 
ARNT Aryl Hydrocarbon Receptor Nuclear Translocator 
ASCT2 Solute Carrier Family 1 Member 5 
ASL Argininosuccinate Lyase 
ASS1 Argininosuccinate Synthase 1 
AT Austria 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
BC Breast cancer 
BRAF B-Raf Proto-Oncogene 
CAD Carbamoyl-Phosphate Synthetase 2 
CH Switzerland  
CI Confidence interval 
Cl Score Cell line Score 
CPS1 Carbamoyl-Phosphate Synthase 1 
DCA Dichloroacetate 
DE Germany 
DKFZ Deutsches Krebsforschungszentrum 
DNA  Deoxyribonucleic acid 
ELISA Enzyme-linked immunosorbent assay 
EPO Erythropoietin 
ER Estrogen receptor 
FASN Fatty Acid Synthase 
FDG-PET 2-(18F)-fluoro-2-deoxyD-glucose positron emission tomography 
FDR False-discovery rate 
FH Fumarate Hydratase 
G1 Gap 1 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
GBM Glioblastoma multiforme 
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GLK Glucokinase 
GLS Glutaminase 
GLUD Glutamate Dehydrogenase 
GLUL Glutamate-Ammonia Ligase 
GLUT Solute Carrier Family 2 Member 
GOT1 Glutamic-Oxaloacetic Transaminase 1 
GPT2 Alanine Aminotransferase 2 
GSH Glutathione 
HER2 Human epidermal growth factor receptor 2 
HIF Hypoxia Inducible Factor 
HR Hazard ratio 
HR Hormone receptor 
HRE Hypoxia response element 
IHC Immunohistochemistry 
IDH Isocitrate Dehydrogenase 
IgG Immunoglobulin G  
LAT1 Solute Carrier Family 7 Member 5 
LDHA Lactate Dehydrogenase A 
LDHB Lactate Dehydrogenase B 
LRM Linear regression model 
MCT4 Monocarboxylate transporter 4 
METABRIC Molecular Taxonomy of Breast cancer International Consortium 
MRM Multiple reaction monitoring 
mTORC1 Mammalian target of rapamycin complex 1 
N Node 
Na Sodium 
NADH Nicotinamide adenine dinucleotide 
NAGS N-Acetylglutamate Synthase 
OAA Oxaloacetic acid 
ODC1 Ornithine Decarboxylase 1 
OS Overall survival 
OXPHOS Oxidative phosphorylation  
p53 Tumor Protein P53 
PAM Prediction Analysis of Microarray 
PCK Phosphoenolpyruvate Carboxykinase 
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PD-1 Programmed cell death protein 1 
PDH Pyruvate Dehydrogenase  
PDK Pyruvate dehydrogenase kinase 
pH Potential of hydrogen 
PHD Prolyl hydroxylase 
PHGDH Phosphoglycerate Dehydrogenase 
PI3K Phosphatidylinositol-4,5-Bisphosphate 3-Kinase  
PKM Pyruvate Kinase, Muscle 
pO2 Partial pressure 
PR Progesterone receptor 
PSAT1 Phosphoserine Aminotransferase 1 
PSPH Phosphoserine Phosphatase 
PVDF Polyvinylidene difluoride 
RFS Recurrence-free survival 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPPA Reverse Phase Protein Array 
RT Room temperature 
SD Standard deviation 
SDHA Succinate Dehydrogenase Complex 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHMT2 Serine Hydroxymethyltransferase 2 
SLC14A1 Urea Transporter 1  
SMS Spermine Synthase 
SREBP1 Sterol Regulatory Element Binding Transcription Factor 1 
SSR Summed square of residuals 
STARD10 StAR Related Lipid Transfer Domain Containing 10 
STEEP standardized definitions for efficacy end points 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
T Tumor 
TAC Thesis advisory committee 
TCA Tricarboxylic acid cycle 
TCGA The Cancer Genome Atlas 
TNBC Triple negative 
TNM Tumor, Node, Metastasis 
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TW Taiwan 
UICC International Union Against Cancer 
UK United Kingdom 
US United states of America 
VEGFA Vascular endothelial growth factor A 
VHL Von Hippel-Lindau 
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